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ABSTRACT
Contribution of Bulky α,β-Dehydroamino Acids to the Proteolytic Stability and
Enhanced Folding of β-Hairpins and Progress Towards the
Total Synthesis of Yaku’amide A
Ankur Jalan
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
This dissertation primarily covers the impact of bulky α,β-dehydroamino acids on the proteolytic
stability and enhanced folding of β-hairpins. It partly describes the progress towards the total
synthesis of yaku’amide A, a potent anticancer peptide with an IC50 value of 14 ng/mL against
leukemia cells. Proteins and peptides are a very attractive source of potential medicinal agents as
they can target various protein–protein interactions that are implicated in several diseases and
disorders. The global sales of peptide drugs in 2013 were estimated to be about $28 billion and are
constantly rising at an appreciable rate. However, peptide drugs have a short plasma half-life
because of their susceptibility to proteolysis. Multiple approaches have been discovered to
overcome this shortcoming, but there is still an urgent need for better peptidomimetics to increase
the stream of peptides entering the pharmaceutical market. Here, it has been demonstrated that the
incorporation of a bulky α,β-dehydroamino acid in the turn regions of β-hairpins can substantially
increase their proteolytic stability and folding. Insertion of a dehydrovaline (ΔVal) residue at the
i+1 position imparted ca. 7-fold increase in proteolytic resistance and ca. 15% increase in folding
when compared to the parent peptide. Since the insertion of a bulky α,β-dehydroamino acid into
the turn regions of β-hairpins can promote proteolytic stability without perturbing the secondary
structures, it is believed that this novel approach is very promising in stabilizing bioactive turncontaining peptides for therapeutic use.

Yaku’amide A is a medium-sized peptide that contains several bulky dehydroamino acids, βhydroxyamino acids and unique N- and C-termini. It has an unprecedented anticancer profile, and
potent bioactivity, hence it was imperative to accomplish its total synthesis to elicit its unique
mode of action and biological target. More efficient methods were developed to synthesize bulky
dehydroamino acids and β-hydroxyamino acids. A regioselective base-free aminohydroxylation
was developed for the synthesis of β-hydroxyamino acids. The major focus was the three-step
synthesis of the N-terminal acyl group from a known compound by a one-pot indium-catalyzed
cross-Claisen condensation/reduction and the synthesis of (2S,3R)-β-hydroxyisoleucine, and
racemic β-hydroxyisoleucine, which are the precursors of E- and Z-dehydroisoleucine.

Keywords: bulky α,β-dehydroamino acids, β-hairpins, proteolytic stability, increased folding,
aminohydroxylation, β-hydroxyamino acids, N-terminal acyl group
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DEHYDROAMINO ACIDS

1.1

Introduction

α,β-Dehydroamino acids (ΔAAs) are non-proteinogenic amino acids with a C α=Cβ double
bond and are often found in several natural products synthesized by microbes, marine organisms
and plants (Figure 1.1).1

Figure 1.1. Dehydroamino acids seen in natural products.
Dehydroalanine (ΔAla) and Z-dehydrobutyrine (ΔZAbu) are both seen in lantibibiotics
such as nisin and subtilin. Nisin, a well-known food preservative, occurs naturally in dairy products
and is innocuous to humans, but highly toxic to bacteria. 2 Several other ΔAAs (tri- and tetrasubstituted) which are encountered in natural products (Figure 1.2. and Figure 1.3) are: Edehydrobutyrine (ΔEAbu), Z-dehydrophenylalanine (ΔZPhe), Z-dehydroleucine (ΔZLeu), Z–
dehydrohistidine (ΔZHis), Z-dehydrotryptophan (ΔZTrp), E- and Z- dehydroisoleucine (ΔZIle and
ΔEIle), and dehydrovaline (ΔVal). E- or Z- dehydrobutyrine (ΔZAbu or ΔEAbu) are seen in
microcystins (1–4) and Pahayokolides A and B (5 and 6, contain both ΔZAbu and ΔEAbu). 3

1

Albonoursin (7), a 2,5-diketopiperazine containing Z-dehydroleucine ((ΔZLeu), and Zdehydrophenylalanine (ΔZPhe) residues, shows antibacterial, antiviral, and anticancer activity.4

Figure 1.2. Natural products with di- and trisubstituted dehydroamino acids.

2

ΔZPhe is also found in other natural products like the phytotoxic cyclic tetrapeptide tentoxin
(8) that is known to cause chlorosis in certain plants. 5 Z-dehydrotryptophan (ΔZTrp) occurs in
several cyclic peptides such as neochinulins (9) (growth inhibitor), telomycin (10) (antibiotic),
keramamide F (11) (cytotoxic), microsclerodermin G (12) (antitumor and antifungal), and cristatin
A (13) (antitumor), with a variety of biological activities. 6 Z–dehydrohistidine (ΔZHis) is another
trisubstituted aromatic dehydroamino acid that is found in natural products. (–)-Phenylahistin ((S)enantiomer) (14), a tubulin polymerization inhibitor, is reported to contain a ΔZHis residue.7
Apart from the trisubstituted dehydroamino acids, several natural compounds contain
tetrasubstituted dehydroamino acids such as the symmetric dehydroamino acid ΔVal, and
asymmetric dehydroamino acids E- & Z- dehydroisoleucine (ΔZIle and ΔEIle) as shown in Figure
1.3. Lasiodine A (15), an acyclic depsipeptide isolated from the African buckthorn plant
Lasiodiscus marmoratus, contains a ΔVal residue and is reported to prevent photophosphorylation
in the chloroplasts of spinach.8 There are multiple examples of natural products that contain both
dehydrovaline and dehydroisoleucine. Myxovalargin A (16), an inhibitor of bacterial protein
synthesis, is characterized by the presence of both ΔVal and ΔEIle in its structure.9 The acyclic
tetradecapeptides yaku’amides A (17a) and B (17b) are found to contain both geometrical isomers
of ΔIle (one ΔEIle and two ΔZIle) and one ΔVal residue. Both of these linear peptides exhibit very
potent activity against P388 murine leukemia cells, with excellent IC50 values of 14 ng/mL and 4
ng/mL respectively. 10 Antrimycins (18a–18h), FR225659 (19a), and its four related peptides
(19b–19e) are characterized by the presence of either ΔVal or ΔEIle. 11 Phomopsins A (20a) and B
(20b), 13-membered lactams, each contain one ΔEIle residue among their six nonproteinogenic
amino acids. Phomopsin A (20a) is reported to inhibit mitosis by binding to β-tubulin. 12

3

Figure 1.3. Natural products with tetrasubstituted dehydroamino acids.
α,β-Dehydroamino acids are non-coded amino acids and their salient feature is a carbon–
carbon double bond between the α and β carbons. This double bond has a profound effect on the
conformational properties of the dehydroamino acid residue as there is an achiral sp2 hybridized
α-carbon instead of the usual chiral sp3 hybridized α-carbon. This in turn can immensely affect the
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overall conformation of a peptide containing a dehydroamino acid residue. α,β-Dehydroamino
acids can be used as inducers of certain folded conformations in peptides and hence, they can
potentially be used to design peptides to target protein-protein interactions. 13

1.2

Methods for α, β-dehydroamino acids (ΔAAs) synthesis
Along with their unique and challenging chemical structures, these natural products

containing α,β-dehydroamino acids (Figure 1.2 and 1.3) are of great importance because of their
wide-ranging biological activities. Hence, multiple methods have been devised to synthesize these
nonproteinogenic amino acids. Some of these methods are covered here.
Since 1893, Erlenmeyer’s condensation has been a well-known procedure for the synthesis
of amino acids and dehydroamino acids from N-protected glycine derivatives. For example, an
azlactone (22) is formed via Perkin-type condensation of N-acetylglycine (21) and benzaldehyde
in the presence of acetic anhydride and anhydrous sodium acetate (Scheme 1.1). This azlactone
can be further elaborated to synthesize desired dehydropeptides. 14

Scheme 1.1. Erlenmeyer’s condensation.
In 1926, Bergmann and co-workers synthesized several azlactones of dehydroamino acids.
N-chloroacetyl amino acids in the presence of acetic anhydride afforded dehydroamino acid
azlactones via cyclization and elimination. Similarly, they obtained the azlactone (26) upon
heating of N-chloroacetyl-β-hydroxyphenylalanine (25) with acetic anhydride, which provided
glycyl–dehydrophenylalanine dipeptide (28) after treatment with water and ammonia (Scheme
1.2).
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Scheme 1.2. Synthesis of azlactones and a dipeptide via azlactone-opening.
In 1943, Bergmann et al. utilized their strategy along with the Erlenmeyer’s condensation
to synthesize many small peptides containing one to four Z-dehydrophenylalanines.15 A protocol
similar to Bergmann’s method was adopted by Ohta and co-workers in 1967 to synthesize the Zdehydroisoleucine residue of albonoursin (7). Heating of N-dichloroacetyl-L-leucine (29) with
acetic anhydride provided the azlactone 30 containing dehydroisoleucine, which was further
manipulated to give albonoursin (7) (Scheme 1.3).16

Scheme 1.3. Synthesis of (Z)-ΔIle residue of albonoursin (7).
Several researchers have prepared dipeptides containing a dehydroamino acid by the
condensation of α-keto acids with carboxamides in the presence of catalytic p-toluenesulfonic acid
(p-TsOH) in refluxing benzene (Scheme 1.4).17

Scheme 1.4. Condensation of an α-keto acid with a carboxamides.
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Stammer et al. reported the synthesis of dipeptide azlactones of ΔZPhe by oxidation of the
azlactone obtained from the dipeptide Z-Pro-Phe-OH. Activation of the dipeptide Z-Pro-Phe-OH
(34) with dicyclohexylcarbodiimide (DCC) gave azlactone 35, which upon oxidation with 2,3dichloro-5,6-dicyano-p-benzoquinone (DDQ) at room temperature furnished the unsaturated
azlactone 36 in 48 % yield (Scheme 1.5).18

Scheme 1.5. Synthesis of (Z)-ΔPhe containing dipeptide azlactone 36 by DDQ oxidation.
Several elimination protocols have been developed for the synthesis of α, β-dehydroamino
acids (ΔAAs) from readily available β-hydroxyamino acids. Various reagents have been employed
to facilitate β-elimination from β-hydroxy α-amino acids, like diethyl chlorophosphate, oxalyl
chloride, tosyl chloride, mesyl chloride, Martin’s sulfurane, triphenyl phosphine/diethyl
azodicarboxylate

(DEAD),

disuccinimidyl

diisopropylcarbodiimide/copper(I)

carbonate

chloride

(DSC),

(DiPCD)

N,N-carbonyldiimidazole,

and

(diethylamino)sulfur

trifluoride/pyridine (DAST).19 It is noteworthy that most of these methods are stereoselective for
the thermodynamically more stable Z-isomer.
Shanzer and co-workers realized the limitations of the previously reported methods as these
protocols mostly afforded the more thermodynamically stable Z-isomer or a mixture of both the
geometrical isomers of asymmetrical α,β-dehydroamino acids.20 In 1983, they reported a one-step
stereospecific method for the synthesis of Z- & E- ΔAbu and ΔLeu by the dehydration of threoand erythro- protected β-hydroxyamino acids (threonine and β-hydroxy-leucine) respectively with
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(diethylamino)sulfur trifluoride in the presence of pyridine via an E2 elimination reaction (Scheme
1.6).

Scheme 1.6. One-step stereospecific dehydration for the synthesis of Z- & E- ΔAbu and ΔLeu.
Later on in the year 2003, Sai and his colleagues reported the stereoselective synthesis of
E- & Z- ΔAbu and ΔPhe from threo- and erythro- threonine and β-hydroxyphenylalanine
respectively via 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and copper (II) chloride
(EDC/CuCl2) mediated dehydration. 21 Unlike the previous work, this method is remarkable as the
cheaper threo-diastereomer selectively afforded the E-isomer.
In order to expand the limited synthetic methodologies available currently for the
stereoselective synthesis of trisubstituted E- α,β-dehydroamino acids, Ohfune et al. developed new
protocols based upon the very reliable and efficient Horner–Wadsworth–Emmons method of
constructing ΔAAs.22 They designed a new Schmidt’s reagent (39) and utilized it to construct a
complex ΔEAA, an important intermediate in their 12-step diastereoselective total synthesis of (–)kaitocephalin. 23 Encouraged by this, they explored optimal conditions for the synthesis of several
E-dehydroamino acids and their derivatives (Scheme 1.7). Aromatic aldehydes such as 2-
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pyridinecarbaldehyde, benzaldehyde, m-nitro & p-methoxy benzaldehyde furnished the E-isomers
in a highly stereoselective manner and in good yields. DBU/MgBr2•OEt2 was required instead of
NaH/NaI to obtain the aliphatic ΔEAA with good E-selectivity.

Scheme 1.7. Synthesis of (E)-ΔAAs by Horner–Wadsworth–Emmons condensation.
1.3

Synthesis of tetrasubstituted bulky α,β-dehydroamino acids
Since bulky tetrasubstituted, dehydroamino acids are commonly seen in biologically active

natural peptides, many attempts have been made to invent simple and efficient methods to
synthesize these unnatural amino acid residues.
While working on β-lactam thiazoline systems for their biogenetic type synthesis of
penicillin and cephalosporin antibiotics, Kishi and co-workers synthesized ΔVal-containing
dipeptide from penicillamine methyl ester (methyl (R)-2-amino-3-mercapto-3-methylbutanoate)
via elimination of the thiol moiety. 24 In 1999, Wandless et al. developed an efficient and
stereospecific method to synthesize tri- and tetrasubstituted α,β-dehydroamino acids by the anti
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dehydration

of

N-acyl-β-hydroxyamino

esters

42

with

thionyl

chloride

and

1,8-

diazabicyclo[5.4.0]-undec-7-ene (DBU) via diastereomeric cyclic sulfamidite intermediates 43.
This two-step antiperiplanar elimination protocol is suitable for dehydration of both the secondary
and tertiary alcohols, and provides both (Z) and (E)-ΔAAs in moderate to good yields (Scheme
1.8). They devised this method to construct an (E)-ΔIle-containing tripeptide intermediate for the
total synthesis of the antimitotic agent phomopsin A (20a, Figure 1.3).25

Scheme 1.8. Synthesis of (Z) and (E)-ΔAAs by the anti dehydration of N-acyl-β-hydroxyamino
esters 42.
Inspired by the syn-dehydration protocol developed by Sai et al., Joullié and co-workers
developed a method for the stereoselective synthesis of (E)-ΔIle found in the phomopsins A and
B (20a and 20b, Figure 1.3) The syn dehydration of dipeptide 45 with EDC/Cu(OTf)2 at 60 ºC in
THF afforded (E)-ΔIle containing dipeptide 46 after 1.5 h in good yield (73 %) (Scheme 1.9).19b

Scheme 1.9. Syn dehydration mediated by EDC/Cu(OTf)2.
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Another important and stereoselective method for the synthesis of ΔAAs is vinyl
amidation.26 During the total synthesis of the anticancer peptide yaku’amide A (17a), Kuranaga
and Inoue synthesized three ΔAAs, (Z)-& (E)-ΔIle and ΔVal, through copper-catalyzed crosscoupling of amides with stereodefined vinyl iodides in good yields. 27 (Z)-ΔIle-containing
dipeptide precursors 49 and 52 were synthesized from amides 47 and 51 with vinyl iodide 52,
whereas (E)-ΔIle-containing dipeptide precursor 56 was obtained by coupling amide 54 with vinyl
iodide 55. Peptide 60 containing ΔVal was synthesized from vinyl iodide 59 and amide 58, but
required a much higher catalytic loading and provided a moderate yield (Scheme 1.10).

Scheme 1.10. Cross-coupling to access tetrasubstituted ΔAAs of yaku’amide A.
All these approaches are useful and have advanced the chemistry of dehydroamino acids
tremendously. However, there were still a few shortcomings. Castle and co-workers addressed
some of these gaps in 2014. They synthesized the critical (Z)- and (E)-ΔIle-containing peptide
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fragments of yaku’amide A with excellent diastereoselectivity via Martin sulfurane mediated
direct stereoselective anti dehydration of tertiary alcohols 61 and 64 respectively (Scheme
1.11).

28

Martin sulfurane has been previously used by Shioiri et al. to synthesize the

thermodynamically favorable (Z)-ΔAbu isomer and ΔVal, but this new method discovered by Ma
and Castle is a rare example of Martin sulfurane mediated concerted asynchronous E2 dehydration
of β-tert-hydroxy amino acids.29

Scheme 1.11. Martin sulfurane mediated anti dehydration of β-tert-hydroxy amino acids.
1.4

Solid-phase synthesis of peptides containing dehydroamino acids and new approaches
for the synthesis of dehydroamino acids by elimination in solution
Solution-phase synthesis of peptides containing α,β-dehydroamino acids has progressed well

since the 1920’s when Bergmann et al. synthesized certain small peptides (dipeptides or tripeptides)
containing Z-dehydrophenylalanine (ΔZPhe) via azlactone intermediates. Several methodologies
have been developed to synthesize dehydroamino acids, such as elimination, condensation, and
cross-coupling. Nevertheless, the solution-phase synthesis has some inherent drawbacks, like the
necessity of purification at every step, low overall yield and its time-consuming nature. Since the
advent of solid-phase peptide synthesis in the mid 1960’s and consequent rapid development of
the orthogonal protecting groups for the amino acid side chain functional groups, solid-phase
peptide synthesis has become the most important tool for the synthesis of medium to large peptides
12

as it can overcome some of the major drawbacks of solution-phase peptide synthesis. Solid-phase
peptide synthesis also allows the preparation of a vast number of structurally diverse peptides for
combinatorial libraries. Hence, researchers tried to adopt this powerful method for the synthesis
of peptides containing α,β-dehydroamino acids. There are multiple examples of on-resin
eliminations, couplings of dipeptides containing a ΔAA to peptides on resin, and chemoselective
eliminations in solution after solid-phase peptide synthesis.
In 1981, Stammer and Chauhan reported the solid-phase synthesis of a few ΔZPhecontaining analogues of the potent vasodilator peptide bradykinin (BK, Arg1-Pro2-Pro3-Gly4-Phe5Ser6-Pro7-Phe8-Arg9). They incorporated ΔZPhe in place of the phenylalanyl residues at positions
5 and/or 8 to synthesize three analogues: [ΔZPhe5]BK, [ΔZPhe8]BK and [ΔZPhe5,8]BK. They
introduced the ΔZPhe into the growing resin-bound peptide by using activated dipeptides with
ΔZPhe at the terminal end of the dipeptides (Scheme 1.12). The dipeptide acids were synthesized
by the DDQ oxidation of saturated azlactones of Boc-Pro-Phe-OH and Boc-Gly-Phe-OH to
corresponding unsaturated azlactones, followed by subsequent alkaline hydrolysis to dipeptide
acids. [ΔZPhe5]BK was synthesized by incorporating the dipeptide acid Boc-Gly-ΔZPhe-OH in the
resin bound peptide with the aid of dicyclohexylcarbodiimide (DCC) at rt over 20 h in methylene
chloride. Boc-Pro-ΔZPhe-OH dipeptide could not be coupled to the peptide successfully by the
same procedure. Hence, Boc-Pro-ΔZPhe-OH was activated with isobutyl chloroformate in THF at
–15 °C in the presence of N-methyl-morpholine. Six equivalents of this activated dipeptide were
required for the coupling to H2N-(tosyl)Arg-resin (Merrifield resin), and the coupling was
complete in ca. 36 hours at rt. This modified procedure was followed to incorporate ΔZPhe8 in the
[ΔZPhe8]BK and [ΔZPhe5,8]BK analogues. The [ΔZPhe5]BK (Arg1-Pro2-Pro3-Gly4-ΔZPhe5-Ser6-
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Pro7-Phe8-Arg9) analogue thus synthesized was found to be more potent than bradykinin at
lowering the blood pressure of rats after intravenous injection. 30

Scheme 1.12. Synthesis of ΔZPhe-containing analogues of bradykinin (BK).
In 1992, Goodman and Polinsky demonstrated the first on-resin dehydration of serine to
obtain ΔAla with N,N'-disuccinimidyl carbonate (DSC) for the synthesis of novel cyclic opioid
peptide [D-AlaL2, L-AlaL5]EA (67, Scheme 1.13). This enkephalinamide analogue was
synthesized on MBHA resin by Boc/benzyl chemistry. The serine residue at position 2 on peptide
69 was then subjected to dehydration with a solution of N,N-disuccinimidyl carbonate (DSC) in
acetonitrile and 5% DIEA in DCM. The S-protecting group fluorenyl methyl (Fm) was cleaved by
treatment with 20% piperidine/DMF and then subjected to 5% piperidine/DMF-DCM (40 mL, 1:1)
overnight for the Michael addition to provide cyclic peptide 72. The peptide 72 was then cleaved
from the resin with anhydrous HF in the presence of anisole at 0 °C to furnish crude cyclic peptide
[D-AlaL2, L-AlaL5]EA 67.31
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Scheme 1.13. On-resin dehydration of serine to ΔAla.
Bradley and co-workers reported the syntheses of a tripeptide and pentapeptide containing
one and two dehydroalanine (ΔAla) residues respectively. They used asparagine as a precursor to
the ΔAla residue. Peptides 73 and 74 were synthesized on the Merrifield resin by standard
techniques (Scheme 1.14). The resin-bound peptides were then subjected to Hofmann degradation
with bis(trifluoroacetoxy)iodobenzene (TIB) (1.5 equiv. for each asparagine) in the
DMF/THF/H2O (1:1:1) solvent system for 10 min, followed by exposure to 1.5 equiv. of pyridine
base for 2 h at rt. The washed resin was then treated with methyl iodide and potassium bicarbonate
(10 equiv. for each asparagine) in methanol for 12 h to affect Hofmann elimination. Though the
overall yields were quite ordinary for such short peptides (23% for the tripeptide 75 and 9% for
the pentapeptide 76), this method can be useful to synthesize branched peptides with the
manipulation of the ΔAla residue. 32
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Scheme 1.14. On-resin Hofmann degradation and elimination of asparagine to ΔAla.
Another method for the incorporation of dehydroalanine into peptides was reported by
Horikawa et al. in 1998, wherein they utilized cysteine as a ΔAla precursor. They synthesized a
few dipeptides on Merrifield resin by tethering the cysteine side chain to the resin. The polymerbound cysteine could be elongated from either its N- or C- terminus.33 m-Chloroperbenzoic acid
(m-CPBA) mediated oxidation of sulfides 78 to sulfones 79 followed by elimination with DBU at
25 °C provided the desired peptides 80 in moderate to good yields (Scheme 1.15).34

Scheme 1.15. Elimination of cysteine derived sulfones to ΔAla.
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Similarly, Bradley and co-workers reported the synthesis of ΔAla via the elimination of an
S-methylcysteine-derived sulfoxide with DBU or by thermolysis in solution. They utilized this
strategy for the synthesis of the A-ring of subtilin (81) by coupling two peptide fragments: one
containing two dehydroalanine residues generated from S-methylcysteine (84), and the other a
dipeptide with a S-tritylcysteine (85, Scheme 1.16). Global deprotection and cyclization yielded
cyclic peptide 81. However, this methodology is not suitable if the peptide contains additional Sprotected cysteine residues.35

Scheme 1.16. Synthesis of ΔAla from S-methylcysteine.
Tam and co-workers reported a similar elimination protocol to generate linear and cyclic
peptides, wherein S-cyanocysteine or S-methylcysteine sulfoxide furnished the ΔAla residue upon
β-elimination. 36
In order to overcome the limitation mentioned above, van der Donk and co-workers
demonstrated that peptides containing ΔAla can be accessed in the presence of oxidation-sensitive
residues like S-protected cysteine, methionine, and unprotected tryptophan by using
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phenylselenocysteine (Sec(Ph)) as the precursor for ΔAla. Peptides were synthesized by standard
Fmoc-t-Bu chemistry, deprotected (cysteine was left protected), and cleaved from the resin. The
purified peptides 87 were subjected to oxidative elimination with NaIO4 /H2O2 at 25 °C for 0.5–2
h in order to transform (Sec(Ph)) into ΔAla with good yields (Scheme 1.17).37

Scheme 1.17. Sec(Ph) as the precursor for ΔAla.
Even though this methodology has not been developed yet for oxidative elimination on the
solid-support, these mild oxidation conditions are compatible with other amino acid functional
groups like amines, guanidines, amides, alcohols and acids.
In 2001, Nakamura et al. reported the synthesis of AM-toxin II (89), a cyclic depsipeptide
containing ΔAla. They developed a novel selenyl anchoring residue (a selenated alanine, 90) which
on oxidative cleavage with tert-butyl hydroperoxide (TBHP) solution reveals the ΔAla residue.
Cyclization and oxidative elimination were performed on the resin to give AM-toxin II (89) from
peptide 91 (Scheme 1.18).38
18

Scheme 1.18. Oxidative elimination of a selenated alanine to ΔAla.
In the same year, Albericio and co-workers reported the first EDC/CuCl-mediated
dehydration of the resin-bound peptides Ac-Tyr(tBu)-Gly-Thr-Phe-Leu-amide-linker-resin and
Ac-Val-Phe-Thr-Val-amide-linker-resin to make thermodynamically stable Z-ΔAbu from
threonine residues. They tried various reagents and conditions for on-resin elimination:
DSC/DIEA, DSC/DABCO, DAST/DIEA, Tos2O/DABCO, TosCl/DABCO, PPh3/DEAD and
EDC/CuCl. Other conditions did not lead to clean dehydration, whereas elimination with EDC
(100 equiv.)/CuCl (30 equiv.) provided clean conversion of the Thr residue to Z-ΔAbu under N2
over 2 weeks in DMF/DCM (1:1) at room temperature. Similarly, they successfully synthesized
small peptides containing ΔAla and (Z)-ΔPhe from L-Ser and D, L- phenylserine respectively. 39
This single step elimination protocol was subsequently used by them in the total synthesis
of kahalalide F (93), an antitumor cyclic depsipeptide (Scheme 1.19). Kahalalide F (93) contains
13 amino acids and exhibits a Z-ΔAbu residue. The linear peptide 94 was synthesized on 2chlorotrityl chloride-resin (Cl-Trt-Cl-resin), and the Z-ΔAbu precursor L-Thr was introduced
unprotected. Elimination on solid-phase was performed by treating the resin-bound peptide 94
19

with EDC (100 equiv.) and CuCl (60 equiv.) at rt for 6 days in DMF: DCM (5:1). The dehydration
of unprotected L-Thr exclusively yielded the Z-ΔAbu.

Scheme 1.19. On-resin dehydration of threonine to Z-ΔAbu in the total synthesis of Kahalalide F
Cyclization and final deprotection were performed in solution on peptide 97 to yield kahalalide F
(93) after Alloc deprotection and cleavage of the protected peptide from the resin (96) under very
mild acid conditions. 40
In 2003, Jiménez and Albericio further reported the utility of the same approach in the
solid-phase synthesis of the Z-ΔPhe-containing phytotoxic cyclic peptide tentoxin (8). Herein, the
dehydration of DL-phenylserine was performed on resin-bound peptide 98 with EDC (40 equiv.)
and CuCl (20 equiv.) for 3 days in DMF (Scheme 1.20).41
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Scheme 1.20. Dehydration of DL-phenylserine to Z-ΔPhe.
Magos and co-workers reported the total synthesis of (–)-phenylahistin (14) and (–)aurantiamine (100) on solid-phase (Scheme 1.21). These 2,5-diketopiperazines contain an
isoprenylated Z-dehydrohistidine, which was constructed by the Horner–Wadsworth–Emmons
protocol. Schmidt’s phosphonate 102 was tethered to the modified Merrifield resin 101 and
coupled to a L-amino acid (Phe or Val), followed by olefination with the aldehyde 106. After Bocdeprotection, the base-promoted amidation yielded the desired natural targets 14 and 100 with their
concomitant cleavage from the resin. This simple strategy was then used to create a library of
dehydro-2,5-diketopiperazines (108–113) by varying the L-amino acid and the aromatic aldehyde.
The mild olefination conditions mainly favored the Z-isomer of the dehydroamino acids formed
except for with the L-proline containing compounds. Though the yields of these compounds are
poor, Magos and co-workers were able to synthesize various trisubstituted aromatic dehydroamino
acids by this method.42
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Scheme 1.21. On-resin synthesis of Z-ΔAA by Horner-Wadsworth-Emmons condensation.
Since the free amine (enamine) of a dehydroamino acid is weakly nucleophilic for the
coupling reaction, the most widely applicable method for the introduction of dehydroamino acids
in peptides is by coupling a small peptide (di- or tripeptide) containing a ΔAA to another peptide
fragment. In 2011, Chauhan and co-workers synthesized several Z-ΔPhe containing cationic
antimicrobial peptides (AMPs) on solid-phase via azlactone dipeptide coupling strategy. They
synthesized several Z-ΔPhe containing azlactones by treating dipeptides of Fmoc-Nα amino acid
(Lys(Boc)/Trp(Boc) /Ala) and DL-threo- β-phenylserine with anhydrous sodium acetate and acetic
anhydride. These azlactones were then coupled to the growing resin-bound peptides overnight in
DMF to incorporate the thermodynamically stable Z-ΔPhe isomer into the resin-bound peptides.43
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Similarly, Castle and co-workers accomplished the solid-phase synthesis of four
octapeptides (114a–114d) containing symmetrical bulky tetrasubstituted dehydroamino acids,
namely dehydrovaline (ΔVal) and dehydroethylnorvaline (ΔEnv). They synthesized analogues of
the C-terminal fragment of the anti-HIV agent enfuvirtide via the ring opening of azlactone
dipeptides 115 by the resin-bound peptides 116 with catalytic DMAP at 60 °C in NMP over 24 h
as shown (Scheme 1.22). Since Fmoc-protected dipeptide azlactones were unstable under the
above conditions, they employed Alloc, an orthogonal protecting group compatible with the
Fmoc/t-Bu solid-phase peptide chemistry that could be easily cleaved under neutral conditions
without affecting the acid-sensitive side chain protecting groups. This is the first reported solidphase synthesis of peptides containing tetrasubstituted dehydroamino acids and opens new avenues
for the rapid synthesis of libraries of symmetrical tetrasubstituted dehydroamino-acid-containing
peptides.44

Scheme 1.22. Solid-phase synthesis of octapeptides containing ΔVal and ΔEnv.
Yamashita and Inoue reported the solid-phase total synthesis of an E-ΔAbu-containing
linear dodecapeptide bogorol A (118) in 2015 (Scheme 1.23). Bogorol A is active against
methicillin resistant Staphylococcus aureus (MRSA, MIC = 2.5 g/mL) and vancomycin resistant
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Enterococcus spp. (VRE, MIC = 9 g/mL). E-ΔAbu is the first amino acid from the N-terminus
region and hence, the remaining eleven amino acids were very easily assembled on the L-valinol
bound to the 2-chlorotrityl resin 119 in order to provide undecapeptide 120. Vinyl azide 121 was
then coupled to 120, and this was followed by traceless Staudinger ligation with phosphine 123.
Acid-promoted global cleavage of the protecting groups and the peptide from the resin yielded
bogorol A (118) in 30% overall yield.45 This mild traceless Staudinger ligation protocol may be
amenable to the solid-phase synthesis of peptides containing dehydroamino acids at any position
in the peptides.46

Scheme 1.23. On-resin synthesis of E-ΔAbu by mild traceless Staudinger ligation.
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1.5

Conclusion
Natural products containing dehydroamino acids are of great importance because of their

biological activities and unique chemical structures. Multiple methods have been discovered for
the synthesis of dehydroamino acids and for their incorporation into peptides. In this chapter, we
covered both the solution-phase and solid-phase methods available for the formation of ΔAAs. It
is important to mention that the synthesis of asymmetrical ΔAAs is quite challenging when the
desired geometrical isomer is not the thermodynamically favored isomer. Currently, there is only
one solid-phase protocol available for the incorporation of bulky tetrasubstituted symmetrical
dehydroamino acids. Rapid solid-phase synthesis of peptides containing ΔAAs can increase the
types of peptidomimetics available to explore the secondary structures of peptides, and can
potentially confer diverse therapeutic benefits.

1.6

References

1. a) Nandel, F. S; Sahrawat, T. R. Biopolymers, 2009, 92, 44; b) Jiang, J.; Ma, Z.; Castle, S. L.
Tetrahedron 2015, 71, 5431.
2. Breukink, E.; Wiedemann, I.; van Kraaij, C.; Kuipers, O. P.; Sahl, H. G.; de Kruijff, B. Science
1999, 286, 2361.
3. a) Sano, T.; Bewattie, K. A.; Codd, G. A.; Kaya K. J. Nat. Prod. 1998, 61, 851; b) Sano, T.;
Kaya, K. Tetrahedron 1998, 54, 463; c) An, T.; Kumar, T. K. S.; Wang, M.; Liu, L.; Gantar, J. O.
L. M.; Marks, V.; Gawley, R. E.; Rein, K. S. J. Nat. Prod. 2007, 70, 730.
4. a) Khokhlov, A. S., Lokshin G. B. Tetrahedron Lett. 1963, 1881; b) Wang, P.; Xi, L.; Liu, P.;
Wang, Y.; Wang, W.; Huang, Y.; Zhu, W. Mar. Drugs 2013, 11, 1035; c) Fukushima, K.; Yazawa,
K.; Arai, T. J. Antibiot. 1973, 26, 175.
5. Cavelier, F.; Verducci, J.; André, F.; Haraux, F.; Sigalat, C.; Traris, M.; Vey, A. Pestic. Sci.
1998, 52, 81.
6. a) Maruyama, K.; Ohuchi, T.; Yoshida, K.; Shibata, Y.; Sugawara, F.; Arai, T. J. Biochem. 2004,
136, 81; b) Sheehan, J. C.; Mania, D.; Nakamura, S.; Stock, J. A.; Maeda, K. J. Am. Chem. Soc.
25

1968, 90, 462; c) Davidson, B. S. Chem. Rev. 1993, 93, 1771; d) Chandrasekhar, S.; Sultana, S. S.
Tetrahedron 2000, 56, 3679; e) Rahman, K. M.; Hossain, M. D.; Sohrab, M. H.; Drake, A. F.; Bui,
T. T.; Husby, J.; Gunaratnam, M.; Neidle, S.; Hasan, C. M.; Thurston, D. E. Chem. Commun. 2012,
48, 8760.
7. a) Kanoh, K.; Kohno, S.; Asari, T.; Harada, T.; Katada, J.; Muramatsu, M.; Kawashima, H.;
Sekiya, H.; Uno, I. Bioorg. Med. Chem. Lett. 1997, 7, 2847; b) Kanoh, K.; Kohno, S.; Katada, J.;
Hayashi, Y.; Muramatsu, M.; Uno, I. Biosci. Biotechnol. Biochem. 1999, 63, 1130; c) Kanoh, K.;
Kohno, S.; Katada, J.; Takahashi, J.; Uno, I. J. Antibiot. 1999, 52, 134; d) Nazari, S. H.; Bourdeau,
J. E.; Talley, M. R.; Valdivia-Berroeta, G. A.; Smith, S. J.; Michaelis, D. J. ACS Catal. 2017, 8,
86.
8. Ravizzini, R. A.; Andreo, C. S.; Vallejos, R. H. Plant Cell Physiol. 1977, 18, 701.
9. Irschik, H.; Reichenbach, H. J. Antibiot. 1985, 38, 1237.
10. Ueoka, R.; Ise, Y.; Ohtsuka, S.; Okada, S.; Yamori, T.; Matsunaga, S. J. Am. Chem. Soc. 2010,
132, 17692.
11. Morimoto, K.; Shimada, N.; Naganawa, H.; Takita, T.; Umezawa, H. J. Antibiot. 1982, 35,
378.
12. a) Edgar, L. E.; Culvenor, C. C. J. Biochem. Pharmacol. 1987, 36, 2133; b) Ludueña, R. F.;
Roach, M. C.; Prasad, V.; Lacey, E. Biochem. Pharmacol. 1990, 39, 1603; c) Mitra, A.; Sept, D.
Biochemistry 2004, 43, 13955.
13. Hajduk, P. J.; Greer, J. Nat. Rev. Drug Discovery 2007, 6, 211.
14. Kaur, H.; Heapy, A. M.; Brimble, M. A. Org. Biomol. Chem., 2011, 9, 5897.
15. Doherty, D. G.; Tietzman, J. E.; Bergmann, M. J. Biol. Chem.1943, 147, 617.
16. Shin, C.; Chigira, Y.; Masaki, M.; Ohta, M. Tetrahedron Lett. 1967, 8, 4601.
17. a) Shin, C.; Yonezawa, Y.; Unoki, K.; Yoshimura, J. Tetrahedron Lett. 1979, 20, 1049; b)
Broda, M. A.; Ciszak, M. A.; Kozioł, A. E.; Pietrzyński, G.; Rzeszotarska B. J. Pept. Sci. 2006,
12, 538.
18. Konno, S.; Stammer, C. H. Int. J. Pept. Protein Res. 1978, 12, 222.
19. a) Goodall, K.; Parsons, A. F. Tetrahedron Lett. 1995, 36, 3259; b) Shangguan, N.; Joullie, M.
M. Tetrahedron Lett. 2009, 50, 6755.
20. Somekh, L.; Shanzer, A. J. Org. Chem. 1983, 48, 907.
21. Sai, H.; Ogiku, T.; Ohmizu, H. Synthesis 2003, 2, 201.
22. Yasuno, Y.; Hamada, T.; Yamada, T.; Shinada, T.; Ohfune, Y. Eur. J. Org. Chem. 2013,
1884.

26

23. Hamada, M.; Shinada, T.; Ohfune, Y. Org. Lett. 2009, 11, 4664.
24 a) Nakatsuka, S.; Tanino, H.; Kishi, Y. J. Am. Chem. Soc. 1975, 97, 5008; b) Nakatsuka, S.;
Tanino, H.; Kishi, Y. J. Am. Chem. Soc. 1975, 97, 5010.
25. Stohlmeyer, M. M.; Tanaka, H.; Wandless, T. J. J. Am. Chem. Soc. 1999, 121, 6100.
26. Jiang, L.; Job, G. E.; Klapars, A.; Buchwald, S. L. Org. Lett. 2003, 5, 3667.
27. Kuranaga, T.; Sesoko, Y.; Sakata, K.; Maeda, N.; Hayata, A.; Inoue, M. J. Am. Chem. Soc.
2013, 135, 5467.
28. Ma, Z.; Jiang, J.; Luo, S.; Cai, Y.; Cardon, J. M.; Kay, B. M.; Ess, D. H.; Castle, S. L. Org.
Lett. 2014, 16, 4044.
29. Yokokawa, F.; Shioiri, T. Tetrahedron Lett. 2002, 43, 8679.
30. Fisher, G. H.; Berryer, P.; Ryan, J. W.; Chauhan, V.; Stammer, C. H. Arch. Biochem. Biophys.
1981, 211, 269.
31. Polinsky, A.; Cooney, M. G.; Toy-Palmer, A.; Osapay, G.; Goodman, M. J. Med. Chem.1992,
35, 4185.
32. Blettner, C.; Bradley, M. Tetrahedron Lett. 1994, 35, 467.
33. Delaet, N. G. J.; Tsuchida, T. Letters in Peptide Science 1995, 2, 325.
34. Yamada, M.; Miyajima, T.; Horikawa, H. Tetrahedron Lett. 1998, 39, 289.
35. a) Burrage, S.; Raynham, T.; Williams, G.; Essex, J. W.; Allen, C.; Cardno, M.; Swali, V.;
Bradley, M. Chem. Eur. J. 2000, 6, 1455; b) Burrage, S. A.; Raynham, T.; Bradley, M. Tetrahedron
Lett. 1998, 39, 2831.
36. Tam, J. P.; Miao, Z. Org. Lett. 2000, 2, 3711.
37. Okeley, N. O.; Zhu, Y.; van der Donk, W. A. Org. Lett. 2000, 2, 3603.
38. Horikawa, E.; Kodaka, M.; Nakahara, Y.; Okuno, H.; Nakamura, K. Tetrahedron Lett. 2001,
42, 8337.
39. Royo, M.; Jiménez, J. C.; López-Macià, A.; Giralt, E.; Albericio, F. Eur. J. Org. Chem. 2001,
45.
40. López-Macià, A.; Jiménez, J. C.; Royo, M.; Giralt, E.; Albericio, F. J. Am. Chem. Soc. 2001,
123, 11398.
41. Jiménez, J. C.; Chavarría, B.; López-Macià, A.; Royo, M.; Giralt, E.; Albericio, F. Org. Lett.
2003, 5, 2115.

27

42. Couladouros, E. A; Magos, A.D. Mol. Diversity 2005, 9, 111.
43. Pathak, S.; Chauhan, V. S. Antimicrob. Agents Chemother. 2011, 55, 2178.
44. Jiang, J.; Luo, S.; Castle, S. L. Tetrahedron Lett. 2015, 56, 3311.
45. Yamashita, T.; Kuranaga, T.; Inoue, M. Org. Lett. 2015, 17, 2170.
46. Yamashita, T.; Matoba, H.; Kuranaga, T.; Inoue, M. Tetrahedron 2014, 70, 7746.

28

RATIONAL DESIGN AND SYNTHESIS OF β-HAIRPIN PEPTIDES

2.1

Introduction
Proteins are among the most important complex biomolecules synthesized by living cells,

and are essential for most of the work done by the cells. Proteins are responsible for the structure,
function, transportation, biocatalysis, immunity, regulation and maintenance of tissues and organs.
Proteins are the key components of spider silk, elk antlers and bacterial flagella. Spider silk is
much stronger than steel, whereas bacterial flagella are microscopic motors. Hence,
thermodynamically stable primary and secondary structures are very vital for the folding of
proteins into highly functionalized and well-ordered tertiary and quaternary structures.
The de novo design of peptides and proteins is of considerable interest to the scientific
community. Rational design and development of peptides as potent agonists or antagonists of
protein-protein interactions may lead to medicinal agents with improved pharmacological and
physico-chemical properties. Apart from utility in the field of medicine, the practical designing of
peptides and proteins can vastly improve the understanding of their folding preferences. Shortrange interactions are comprised of the unique conformational propensity of each amino acid and
interactions of its side chain with the backbone and the side chains of adjacent residues. These
interactions are essential for the determination of preferred conformations. Peptides can adopt a
large number of possible conformations in order to attain the preferred short-range effects. Hence,
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it is significant to devise new strategies to rigidify the peptide backbone to limit the number of
desired peptide conformations.1

2.2

Conformational studies of peptides containing α,β-dehydroamino acids (ΔAAs)
As dehydroamino acids can impart proteolytic stability to a peptide, they are a very attractive

tool for the synthesis of stable secondary structures. In the last few decades, α,β-dehydroamino
acids (ΔAAs) have been used to constrain peptide conformations because of their rigidifying
conjugated Cα=Cβ system and steric bulkiness. ΔAla tends to form extended conformations,
whereas tri- and tetrasubstituted ΔAA residues have been shown to form stable secondary
structures because of their relatively bulkier β substituents.2 Considerable research has been done
in the last few decades to investigate the role of ΔAAs in the stability of α-helices, 310-helices and
β-turns.

2.2.1 Conformational studies of peptides containing trisubstituted ΔAAs
Several trisubstituted dehydroamino acid containing peptides were studied in the 1980’s
and 1990’s for their conformational preferences. X-ray crystal structures of 19 peptides with either
ΔPhe or ΔLeu were studied by Singh et al. in 1990. They revealed that these dehydroamino acid
residues can be suitable inducers for type II β-turns and that consecutive ΔPhe residues can induce
a helix. 3 In their extensive review of 49 peptide units containing ΔAA residues, Singh and coworkers detailed that small peptide units like 124–127 can adopt type II β-turns when a ΔAA is
placed at either the (i+1) or (i+2) position (Table 1.).4 The ideal φ and ψ values in a type II β-turn
are: –60 and 120 (i+1 residue) and 80 and 0 (i+2 residue).
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Table 2.1. ΔAAs at i+1/ i+2 positions of β-turns.
Peptides (ΔAA position)

φ

ψ

Ac-ΔPhe-NHCH3 (124)( ΔPhe at i+1)

–58.3

148

Ac-ΔPhe-Ala-OH.H2O (125) (ΔPhe at i+1)

–68

147

Boc-Gly-ΔPhe-NHCH3 (126) (ΔPhe at i+2)

71.5

7.2

Boc-Pro-ΔLeu-NHCH3 (127) (ΔLeu at i+2)

74

8

They also observed the formation of 310-helices by ΔAA-containing peptides longer than
four residues. Peptides containing a single (Z)-ΔPhe residue do not adopt an optimum 310-helical
conformation, but peptides containing more than one (Z)-ΔPhe can adopt a well-formed 310-helix
with intramolecular hydrogen bonds that are suitably oriented except at the termini. 5
Singh et al. observed that two consecutive (Z)-ΔPhe segments at the (i+2) and (i+3)
positions in small peptides promote a stable 310-helical conformation. If two repeating units of
consecutive (Z)-ΔPhe residues are separated by a saturated amino acid residue as in Boc-Val-ZΔPhe-Z-ΔPhe-Val-Z-ΔPhe-Z-ΔPhe-Val-OCH3 (128), the 310-helical structure formed is highly
stable and does not fray at the two termini which is otherwise usually observed (Table 2.). 6
Residues in a 310-helix typically adopt φ and ψ values of –49 and –29.
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Table 2.2. Torsional angles of ΔPhe in the 310-helix 128.

φ

Peptide

–54.6 (i+2)

ψ
2

–18.7 (i+2)2

–52.2 (i+3)3 –17.5 (i+3)3
Boc-Val1-ΔPhe2-ΔPhe3-Val4-ΔPhe5-ΔPhe6-Val7-OCH3

–61.5 (i+2)5

–7.9 (i+2)5

–49.7 (i+3)6 –30.9 (i+3)6
Note: Superscripts denote the residue positions
Chauhan and co-workers prepared several peptides containing two or three ΔPhe residues,
which adopted a right-handed 310-helical structure. They demonstrated that two consecutive ΔPhe
residues (Boc-Leu-Z-ΔPhe-Z-ΔPhe-Ala-Phe-NHMe) or two ΔPhe residues separated by 1–3
saturated amino acids (Boc-Gly-Z-ΔPhe-Leu-Z-ΔPhe-Ala-NHMe, Boc-Val-Z-ΔPhe-Leu-Ala-ZΔPhe-Ala-OMe and Boc-Val-Z-ΔPhe-Phe-Ala-Phe-Z-ΔPhe-Val-Z-ΔPhe-Gly-OCH3) can induce
formation of right handed 310-helices. The nonapeptide Boc-Val-ΔPhe-Phe-Ala-Phe-ΔPhe-ValΔPhe-Gly-OMe (129) contains seven overlapping type III β-turns because of seven (i+3)(i)
intramolecular hydrogen bonds and adopts a right-handed 310-helix. 7
Mathur and Chauhan studied antimicrobial peptides that adopt helical conformations. So,
they postulated that the introduction of Z-ΔPhe may stabilize the helical structures further and
synthesized cecropin-mellitin hybrid peptides. They synthesized three analogues of cecropinmellitin hybrid peptide CAMEL0 (Lys-Trp-Lys-Leu-Phe-Lys-Lys-Ile-Gly-Ala-Val-Leu-Lys-ValLeu) and found that CAMELΔPhe2 (Lys-Trp-Lys-Leu-ΔPhe-Lys-Lys-Ile-Gly-Ala-Val-ΔPheLys-Val-Leu) has much better antimicrobial activity than the parent peptide CAMEL0.
CAMELΔPhe2 adopts a 310-helix and a β-turn. 8 Chauhan et al. synthesized a lysine-based
branched dimer ΔFd, growing from both α and  amino groups of lys10. This cationic dimer ΔFd
(Ac-G-ΔPhe-R-K-ΔPhe-H-K-ΔPhe-W-A-K (amide NH2)-A-W-ΔPhe-K-H-ΔPhe-K-R-ΔPhe-G-
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Ac) (130) exhibited potent antimicrobial activity against E. coli (MIC of 2.5 M) and S. aureus
(MIC of 5.0 M) and is noncytotoxic (Figure 2.1).9
In 2011, Chauhan and co-workers reported the synthesis of amphipathic helical peptide
VS2 (131) which is very active against Gram-negative bacteria (MIC of 5.0 M) and causes very
low hemolysis. This noncytotoxic undecapeptide has good cell permeability, and can depolarize
the bacterial membrane. Such proteolytically stable, short antimicrobial peptides can usher in a
new era in the discovery and development of novel antimicrobials (Figure 2.1).10

Figure 2.1. Dimer ΔFd (130) and VS2 (131).
It has been reported that β-sheet breakers can prevent the aggregation or formation of βamyloid fibrils. Short peptides containing Pro and Aib residues can inhibit the amyloid
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fibrillization. 11 Chauhan and co-workers synthesized two analogues of the 16–20 fragment (AcK-L-V-F-F-NH2) of the Aβ sequence, which is implicated in the transformation of Aβ monomers
to amyloid fibrils. The electron microscopic studies of these two analogues 132 (Ac-K-L-ΔPheV-F-NH2) and 133 (Ac-K-L-V-ΔPhe-F-NH2) revealed their potent antifibrillizing activity. 12
Similarly, Giordano et al. reported the synthesis of pentapeptides 134-135 containing two
consecutive ΔPhe residues, which can prevent the formation of amyloid fibrils (Figure 2.2).13
Mishra and Chauhan also reported the synthesis of two short peptides 136 and 137, which could
prevent the fibrillization of human islet amyloid polypeptide (hIAPP). hIAPP fibrillization leads
to the formation of oligomers that are toxic to the pancreatic β-cells and can cause Type 2 diabetes.
X-ray crystallography of peptide 136 showed that it adopts a type I β-turn in crystal form.14

Figure 2.2. β-sheet breakers.
2.2.2 Conformational studies of peptides containing tetrasubstituted ΔAAs
Since bulky tetrasubstituted α,β-dehydroamino acids are hard to construct, their roles in
the conformational preferences of peptides are underexplored. Nonetheless, a few studies were
performed and revealed the turn-inducing potential of some tetrasubstituted ΔAAs. Rzeszotarska
et al. showed that ΔVal at the (i+2) position of dipeptide 138 can induce a type III β-turn, whereas
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Singh and coworkers reported that ΔVal in dipeptide 139 can adopt suitable  (–44.2) and 
(135.9) angles for incorporation at the (i+1) position of a type II β-turn (Figure 2.3).15

Figure 2.3. Promotion of β-turns by ΔVal.
Further, in 2003 Vijayaraghavan and Singh reported the inclusion of ΔVal and ΔIle at the
(i+1) position of a type II β-turn in two tripeptides Cbz-ΔVal-Ala-Leu-OMe (140) and Cbz-ZΔIle-Ala-Leu-OMe (141).16 The X-ray crystallographic studies of these peptides reveal that both
the peptide structures were stabilized by intramolecular (i+3)(i) hydrogen bonds between the
NH (amide) of Leu and the O of the carbobenzoxy (Cbz) group. Corroborating the studies of Singh
and co-workers, Rzeszotarska et al. reported the preference of ΔVal to adopt very ideal (i+1)
torsional angles ( = –60 and  = 125) in Ac-ΔVal-NMe2 (142) to form a type II/VIa β-turn
(Figure 2.4).17

Figure 2.4. Induction of type II β-turn.
Apart from the conformational preference for β-turns, Singh et al. also showed that a ΔVal
at (i+1) and ΔPhe at (i+3) positions can induce a 310-helical conformation in similar fashion to the
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incoroporation of two or more ΔPhe residues. A ΔVal residue at the (i+1) position favors a type
II-β-turn and a ΔPhe surrounded by branched β-carbon amino acids prefers unfolded
conformations, but their unique combination in Cbz-ΔVal-Val-ΔPhe-Ile-OMe adopts a 310-helical
conformation. 18

2.3

β-Hairpins
Most of the protein secondary structures observed in nature can be categorized as α-helices,

β-turns and antiparallel β-sheets. Folding of proteins to the correct single structures is very vital
for cellular functions, and misfolding is very often associated with diseases or disorders. α-Helices
and β-turns are widely studied, and our understanding of the noncovalent forces that can induce or
stabilize such secondary structures has improved. However, β-sheets have been less explored
owing to the lack of a good model system for their studies. Hence, investigating the factors that
govern β-sheet formation can help in the rational de novo design of new peptides or proteins with
medicinal activities and better understanding of the pathological conditions caused by protein
aggregation or misfolding.
A β-hairpin, constituting two short antiparallel β-strands with a connecting loop, is a
minimum representation of a β-sheet. Along with the turn sequence, the strand sequence has also
been shown to be significant in the formation of a stable β-hairpin. Since the discovery of the first
β-hairpin by Blanco et al. in 1993, several guidelines have emerged for the formation of stable βhairpins. 19 The turn sequence (residues at i+1 and i+2) is one of the most important factors in the
formation of the β-turn, but the β-sheet propensities of the strand residues and interstrand
sidechain–sidechain interactions are also significant for the genesis of a stable β-hairpin. 20 Studies
by Sibanda et al. have shown that type I and type II are usually associated with β-turns, but a βhairpin (two-residue loop) formation typically requires type I' and type II' β-turns in order to be
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compatible with the right-handed twist of the β-sheets. 21 Ramírez-Alvarado and coworkers
designed a dodecapeptide (BH8, NH2-RGITVNGKTYGR-NH2) with asparagine-glycine in the
loop. NMR data revealed that BH8 exhibited 37% folded population at 274 K in water and formed
a type I' β-turn.22
L-Pro at the (i+1) position in a loop is known to strongly favor type I/II β-turns and hence,
should not be amenable to the formation of a β-hairpin with a two-residue loop. In early 1996,
Haque and Gellman reported that D-Pro-D-Ala/D-Pro-Gly in tetrapeptides (Ac-L-Val-D-Pro-GlyL-Leu-NMe2 and Ac-L-Val-D-Pro-D-Ala-L-Leu-NMe2) and analogous depsipeptides induced βhairpin formation.23 Shortly thereafter, Balaram et al. reported the formation of a type II' β-turn in
octapeptide 143 containing a D-Pro-Gly loop (Boc-Leu-Val-Val-D-Pro-Gly-Leu-Val-Val-OMe).
X-ray crystallography of this octapeptide revealed four intramolecular hydrogen bonds between
the two strands and favorable torsional angles for a type II' β-turn: i+1 = +53 and  i+1 = –132
for D-Pro and i+2 = –96 and  i+2 = +9 for Gly (the ideal values are i+1 = +60,  i+1 = –120
and i+2 = –80,  i+2 = 0).24 Supporting their earlier study, Gellman et al. established that DPro-Gly can induce stable β-hairpin formation by incorporating this turn sequence in the Nterminal segment of ubiquitin, MQIFVKTLTGKTITLEV (144). They slightly modified the strand
sequence of 144 and also introduced D-Pro-Gly instead of the LTG turn (three-residue loop) to
obtain the 16-mer MQIFVKSpGKTITLKV-NH2 (145), which adopted a β-hairpin conformation
in aqueous solution.

25

Further, Stanger and Gellman synthesized two 12-mers of

RYVEVXGOKILQ-NH2 to demonstrate that a D-Pro-Gly (X= D-Pro, peptide 146) sequence is
superior to L-Asn-Gly (X= L-Asn, peptide 147) in the nucleation of a β-hairpin. 26
Though the role of the turn sequence in the formation of a β-hairpin with a two-residue
loop is very vital as explained above, there are several other factors that also contribute to the
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stability of a β-hairpin, namely interstrand (cross-strand) hydrogen bonding, interstrand sidechain–
sidechain interactions (hydrophobic or electrostatic), and β-sheet propensity of the strand residues.
Various researchers have shown the role of each of these factors in the stability of a β-hairpin.
Gellman et al. studied the role of hydrophobic interactions between W2, Y4, F9 and V11 in R-WQ-Y-V-p-G-K-F-T-V-Q-NH2 and established their stabilizing impact on the well-folded βhairpin. 27 Waters et al. showed the significance of van der Waals and/or electrostatic interactions
over hydrophobic interactions in the stabilizing effect of aromatic interactions (sidechain–
sidechain). 28 This was later supported by Balaram and coworkers. 29 Apart from this, Waters’
laboratory also demonstrated the stabilizing impact of diagonal and lateral cation–π interactions
(electrostatic forces) between aromatic and basic residues in several β-hairpins.30 Certain amino
acids have higher propensity to form β-sheets and are shown to favor β-hairpin formation when
included in the strands.31 Hence, a careful consideration is required to design a stable β-hairpin
peptide in order to balance all the stabilizing factors.

2.4

Hypothesis and synthetic strategy for the solid-phase synthesis of β-hairpins containing
bulky α,β-dehydroamino acids
As discussed earlier in Section 2.2, ΔAAs can be used to induce secondary structures like

310-helices and β-turns. Bulky tetrasubstituted α,β-dehydroamino acid residues like ΔVal and ΔIle
have been reported to form β-turns. Since ΔAAs are achiral, they can induce type I' or type II' βturns which are often seen in stable β-hairpins. Hence, it is a very rational proposition that these
dehydro residues can be incorporated in the loop of a β-hairpin. We hypothesized that bulky α,βdehydroamino acids like dehydrovaline (ΔVal) and dehydroethylnorvaline (ΔEnv) can
significantly restrict the rotation of the peptide backbone because of very high levels of inherent
A1,3-strain (allylic strain). This restricted rotation can lead to increased rigidity, more stable folded
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states, and greater stability to proteolysis. The increased A1,3-strain of bulky ΔAAs should stabilize
a peptide more significantly than the moderate A1,3-strain of the smaller trisubstituted ΔAAs
(Figure 2.5).

Figure 2.5. Comparison of tri- and tetrasubstituted ΔAAs.
These bulky ΔAAs should also be less susceptible to Michael addition, which is usually
observed with di- and trisubstituted ΔAAs. Therefore, we proposed that a secondary structure like
a β-hairpin could be significantly stabilized to proteolysis by the substitution of either (i+1) or
(i+2) loop residue with a bulky tetrasubstituted ΔAA.

2.4.1 Synthetic strategy for the solid-phase peptide synthesis (SPPS) of β-hairpins
containing ΔAAs (ΔVal or ΔEnv)
Encouraged by their work on the tetradecapeptide yaku’amide A, Castle and co-workers
became interested in exploring the effects of bulky α,β-dehydroamino acids on peptide structure
and stability. In 2014, they reported the synthesis of four octapeptides containing bulky ΔAAs via
solid-phase peptide synthesis (Scheme 2.1).32 We employed the same synthetic strategy to prepare
several β-hairpins (152). The Fmoc-group was reported to be unstable under the coupling
conditions, hence Alloc-protected dipeptide azlactones were synthesized for coupling to the resinbound peptides.
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Scheme 2.1. Solid-phase peptide synthetic strategy.
Waters and coworkers reported the synthesis of a very stable and well-folded β-hairpin
153a (Figure 2.6).30c, 33 We selected this as a model β-hairpin for testing our hypothesis by
replacing the (i+1) or (i+2) residue with a bulky tetrasubstituted ΔAA. The scheme outlining the
design of analogues is given below. This is a fairly short peptide and amenable to 2D NMR studies
for the elucidation of its structure.

Figure 2.6. Waters’ β-hairpin (153a) and design of analogues (152).
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2.5

Solid-phase peptide synthesis (SPPS) of β-hairpins containing ΔAAs (ΔVal or ΔEnv) in
the NG loop
As outlined in Scheme 2.1, we embarked upon the synthesis of the dipeptide azlactones (149)

required for the preparation of ΔAAs (ΔVal/ΔEnv) containing β-hairpins. Castle et al. had reported
the synthesis of β-hydroxyamino acids via base-free aminohydroxylation. 34 We used the same
successful methodology for the synthesis of racemic mixtures of β-hydroxyvaline (154a) and βhydroxyethylnorvaline (154b) derivatives (Scheme 2.2).

Scheme 2.2. Synthesis of β-hydroxyvaline derivative (154a) via aminohydroxylation.
The yields for the synthesis of bulkier β-hydroxyethylnorvaline were slightly less than βhydroxyvaline (Scheme 2.3). Alloc-protected amino acids 155 were synthesized as described in
the literature.35
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Scheme 2.3. Synthesis of β-hydroxyethylnorvaline derivative 154b via aminohydroxylation.
Alloc-protected amino acids were coupled with β-hydroxyvaline (154a) and βhydroxyethylnorvaline (154b) derivatives to give dipeptides 148 in good yields. Saponification of
the purified dipeptides with LiOH•H2O yielded dipeptide acids 165. As expected, activation of
these acids with acetic anhydride and anhydrous sodium acetate in anhydrous THF yielded the
desired dipeptide azlactones 149 in good yields. Acetic anhydride was used as a solvent for this
cyclization and elimination previously, but the challenges of completely removing the high-boiling
acetic anhydride dissuaded us from continuing with it. Hence, we successfully modified the
previously established protocols by employing 5.0 equivalents of acetic anhydride to facilitate this
cyclization and dehydration to give azlactones 149 (Scheme 2.4). These azlactones were
susceptible to partial decomposition during the flash chromatography purification on silica gel
(SiO2). Hence, the yields of pure dipeptide azlactones 149 were slightly lower. In general, the
quality of crude dipeptide azlactones was sufficient for direct use in couplings to the resin-bound
peptides 150.
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Scheme 2.4. Synthesis of dipeptide azlactones 149.
Peptides 150 were synthesized by standard Fmoc/t-Bu protocols on Rink amide resin, and
a small amount was analyzed by mass spectrometry before coupling with the azlactones. We
initially tried the procedure reported by Jiang and co-workers. Azlactone 149aa was subjected to
coupling with dried resin-bound peptide 150a under Ar by heating the suspension at 60 °C for 24
h in dry NMP. Analysis by mass spectroscopy did not show any coupling of the azlactone to the
peptide. Hence, 0.1 equivalent of DMAP was added to the reaction, but there was no improvement.
Optimum conditions for azlactone 149aa ring opening were then explored and are listed in the
table below (Table 2.3).
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Table 2.3. Screening of ring-opening conditions for the dipeptide azlactone 149aa.

Solvent

Base

Equivalence of
base

Temperature

Extent of
coupling after
24 h

NMP

DMAP

0.5

60–100 °C

Poor

DMF

DMAP

0.5

60–100 °C

Poor

NMP/DMF (1:1)

DMAP

0.5 to 2.0

60–100 °C

Poor

NMP

NEt3

1.0 to 5.0

35–80 °C

Poor to
moderate

NMP

NEt3

10.0

80 °C

Good

During the optimization, we realized that the integrity of the resin deteriorated over time
at elevated temperatures with high rate of stirring. Hence, the reactions were then stirred at low
speeds to prevent the loss of resin integrity. Similar ring-opening conditions were used for all other
dipeptide azlactones. Bulkier azlactones 149ab, 149ba and 149bb required longer periods for
coupling. After the ring opening, we capped the unreacted free amines of the resin-bound peptide
150 with Ac2O to prevent the formation of undesired peptides, which could cause difficulty in the
final purification (Scheme 2.5). Alloc-deprotection of peptide 151 with Pd(PPh3)4 and PhSiH3
proceeded smoothly, and peptides were then elaborated in a straightforward fashion. Nevertheless,
the coupling of the final amino acid Arg required a longer time. All the peptides were then Nacetylated and cleaved from the resin with simultaneous global deprotection of the sidechain
protecting groups. The peptides 152 were lyophilized and subsequently purified by HPLC. 36
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Scheme 2.5. Solid-phase synthesis of β-hairpins (152aa–152bb).
2.6

Solid-phase peptide synthesis (SPPS) of β-hairpins containing D-Pro at (i+1) and ΔAAs
(ΔVal or ΔEnv) at (i+2) positions
Preliminary NMR studies and proteolysis experiments of peptide 152aa were very

encouraging. The peptide exhibited significant folding and stability to proteolysis. Motivated by
these results, we set out to test if we could combine the stabilizing structural and proteolytic effects
of ΔAAs with other stabilizing elements without hampering the β-hairpin structure. The D-ProGly loop is known to promote β-hairpin formation, and a D-residue also imparts stability to
enzymatic degradation. Hence, we slightly modified Waters’ β-hairpin and synthesized two (i+2)
ΔAA (ΔVal or ΔEnv) analogues 152ca and 152cb (Scheme 2.7) of Ac-R-W-V-E-V-p-G-O-K-IL-Q-NH2 (153b). Dipeptide azlactones 149ca and 149cb were synthesized in good yields by the
reproducible protocol described earlier in Section 2.5. The scheme outlining their synthesis is
shown below (Scheme 2.6).
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Scheme 2.6. Synthesis of dipeptide azlactones containing D-Proline (149ca and 149cb).
Azlactone coupling to the resin-bound peptide was also straightforward and surprisingly
proceeded with very good conversion. Alloc-deprotection, peptide elaboration, cleavage and
purification of the peptides were uneventful and afforded peptides (152ca and 152cb) in
moderately good yields (Scheme 2.7).

Scheme 2.7. Solid-phase synthesis of β-hairpins containing D-Pro at (i+1) and ΔAAs (ΔVal or
ΔEnv) at (i+2) positions.
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2.7

Solid-phase peptide synthesis (SPPS) of cyclic controls and random coils for β-hairpins
153a and 152aa
In order to elucidate and precisely compute the population of folded β-hairpins containing a

bulky ΔAA, a cyclic control and two random coils containing a bulky ΔAA were synthesized.
There are remarkable shifts in the Hα proton chemical shifts in a secondary structure.29 Hence,
cyclic control (100% folded) and random coils (0% folded controls) are required to accurately
calculate the percent folded population. We synthesized the cyclic control 167a and random coils
(Ac-R-W-V-E-V-N-G-NH2, 168a and Ac-N-G-O-K-I-L-Q-NH2, 168b) for the model β-hairpin
Ac-R-W-V-E-V-N-G-O-K-I-L-Q-NH2 (153a) by the standard fmoc/t-Bu method. The disulfide
bridge in the cyclic control 167a was established by air oxidation of the purified peptide 166a in
10 mM phosphate buffer solution (pH 7.5) containing 5% DMSO to affect cyclization (Scheme
2.8).30c

Scheme 2.8. Synthesis of cyclic control (167a).
Similarly, we synthesized the cyclic control 167b and random coils 168c and 168d to
calculate the percent folding of 152aa. The dipeptide azlactone ring-opening protocol was
successfully utilized to construct the control peptides. Random coils Ac-R-W-V-E-V-ΔVal-G-
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NH2 (168c) and Ac-ΔVal-G-O-K-I-L-Q-NH2 (168d) were synthesized from dipeptide azlactone
149aa and the azlactone Ac-ΔVal respectively.37 Cyclic controls contain a Cys residue each at the
two termini of the β-hairpin, which are then oxidized to form a disulfide bond to afford a cyclic
peptide. Dipeptide azlactone 149aa was utilized to synthesize the cyclic control. The purified
peptide 166b was oxidized as described above to give 167b (Scheme 2.9).

Scheme 2.9. Synthesis of cyclic control containing ΔVal at (i+1) position (167b).
2.8

Summary
Insights into the factors that govern protein folding are of tremendous interest and can be

extremely useful in designing new rules for the de novo synthesis of stable peptides or proteins.
There are various noncovalent forces that control the folding of peptides or proteins into secondary
structures, which consequently decide their tertiary and quaternary structures. Better
understanding of these factors may help in the rational design and synthesis of peptides or proteins,
which can be used to target certain protein–protein interactions. A specifc conformation is usually
needed for a peptide or protein to elicit its biological activity. These novel peptides and proteins
can be tuned to have desired pharmacological activities, proteolytic stability and pharmacokinetic
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properties. In the last 2–3 decades, β-hairpins have emerged as good monomeric, non-aggregating
and water-soluble model systems for the underexplored β-sheets. Dehydroamino acid residues
have been shown to promote secondary structures like 310-helices and β-turns, hence we designed
and synthesized several well-folded β-hairpins 152aa–152cb by substituting the (i+1) or (i+2)
residues with ΔVal/ΔEnv in two model β-hairpins 153a and 153b.
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CONTRIBUTION OF BULKY α,β-DEHYDROAMINO ACIDS TO THE
PROTEOLYTIC STABILITY AND ENHANCED FOLDING OF β-HAIRPINS

3.1

Introduction
Peptides and proteins play an important role in modern medicine because of their diverse

therapeutic applications. Peptide-based drugs like antimicrobial peptides (e.g., vancomycin,1a
bleomycin,1b

lantibiotics,1c

etc.),

anticancer

agents

(goserelin,1d

bortezomib,1e etc.),

immunomodulators (cyclosporine1f), anti-HIV agents (enfuvirtide1g), and antidiabetic agents
(exenatide1h), are widely used. 1 The global market for therapeutic peptides (insulin and its
derivatives included) was estimated to be ca. $50 billion in 2015 and is growing annually by more
than 10%. Since 2000, 28 new peptide-based drugs (non-insulin derivatives) have entered the
market with good success. 2 However, the major drawbacks of therapeutic peptides are their
susceptibility to rapid proteolysis (i.e. degradation by enzymes) and poor bioavailability. Though
various promising approaches have been devised to overcome these problems (e.g., peptoids, 3 βpeptides, 4 D-peptides, 5 α,α-disubstituted amino acids, 6 stapling, 7 hydrogen bond surrogates, 8
PEGylation9), there is still a great need for better alternatives to stabilize therapeutic peptides.

3.2

Potential of therapeutic peptides and associated challenges
Protein–protein interactions (PPIs) have emerged as highly attractive targets for medicinal

chemists because they are implicated in several human diseases and disorders, including various
types of metabolic disorders and cancers.10 Though more than 12 small-molecule PPI modulators
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are in clinical trials currently, their size is not often ideal to interact with the PPI interface. 11 PPI
interface or contact area is generally large and is relatively featureless with no preformed binding
pockets for small molecules. 12 The salient feature of a PPI interaction surface is a collection of a
few very small binding sites called “hot spots,” which are scattered over the interaction surface.
These hot spots are critical for the competitive binding of the PPI inhibitors. 13 Hence, an inhibitor
has to be sufficiently large to interact with multiple hot spots to modulate the PPI. 14 Several
biologics that target extracellular proteins are available on the market, but their size is huge and
they cannot penetrate the cells to affect intracellular PPIs. Peptides are uniquely positioned
between small molecules and biologics because of their moderate size and high affinity for protein
targets. Their specific three-dimensional conformations make them highly selective, potent and
less toxic.15 Importantly, they can be used to target both extracellular and intracellular PPIs.
As mentioned earlier, peptides are prone to rapid proteolysis and quick hepatic and renal
clearance. Hence, unmodified peptides are generally poor drug candidates. Well-folded peptides
are more efficient as they are less susceptible to degradation than their unfolded counterparts, and
are more likely to be taken up by the cells in a conformationally rigid form. Given their high
therapeutic potential, several strategies have emerged in the last two decades to synthesize
stabilized peptides with well-defined three-dimensional structures.
α-Helical peptides are reported to be involved in many PPIs, and several methods were
thus developed to synthesize stabilized α-helices for modulating the PPIs. Some of the most
common techniques are stapled peptides (all-hydrocarbon cross-linking of sidechains), hydrogen
bond surrogates (HBS) and β-peptides (Figure 3.1). 16 In 2000, Verdine and co-workers
synthesized several short α-helices by cross-linking two side-chains through the olefin-metathesis
reaction. This ruthenium catalyzed ring closing metathesis (RCM) was performed on solid support
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to form an 11-carbon cross-link between the i and i+7 residues. This peptide exhibited a 44%
increase in folding and a 41-fold improvement in the half-life against trypsin digestion when
compared to the unmodified peptide. 17 A well-folded peptide has fewer amide bonds exposed to
the solution and is consequently less susceptible to rapid enzymatic degradation. This strategy has
become very attractive for synthesizing several α-helical PPI inhibitors. Walensky et al.
synthesized a stapled α-helical BH3 (Bcl-2 homology 3) peptide to target the BID (BH3interacting domain death agonist) protein in vivo to kill cancer cells by promoting apoptosis.18
Bernal and Walensky demonstrated that the p53 tumor suppressor pathway could be reactivated
by a stapled helical peptide by modulating the p53-MDM2 protein interaction.19 Similarly, in 2013,
Aileron Therapeutics reported reactivation of the p53 tumor suppression pathway by dual
inhibition of MDM2/MDMX with the stapled helical peptide ATSP-7041.20 Several other cancerinducing PPIs were targeted by stapled peptides such as MCL1-NOXA (small-cell lung cancer)
and the EZH2-EED complex (leukemia). 21 Debnath et al. synthesized the anti-HIV-1 α-helical
stapled peptide (NYAD-1) that can penetrate cells and target the HIV-1 capsid. 22

Figure 3.1. Some common methods of stabilizing peptides.
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Arora and co-workers developed an alternative to stapled peptides. They stabilized α-helices
by replacing the intramolecular ii+4 hydrogen bond at the N-terminus of a short peptide with a
covalent hydrocarbon linkage via ring-closing metathesis. Since the peptide sidechains are not
altered in this hydrogen-bond surrogate (HBS) method, it retains its entire functional surface for
interaction with the protein target.23 They reported the inhibition of gp41-mediated HIV-1 fusion
into the cells by the conformationally constrained α-helical peptide HBS α 9 (EC50 = 43 M).24
β-peptides and peptoids are the other popular methods where oligomers are synthesized from
β-amino acids and N-substituted glycine units respectively. Seebach et al. showed that amphiphilic
314-helical β-peptides can inhibit lipid and cholesterol absorption by small intestinal brush-border
membrane vesicles. These left-handed β-peptides can mimic the right-handed 3.613-helical αoctadecameric motif commonly seen in human apolipoproteins (involved in fat transport and
uptake) and thereby inhibit the function of apolipoproteins. 25 Gellman et al synthesized β-peptides
and mixtures of α- and β-peptides to target the MDM2-p53 interaction.
Despite the recent advances in peptide modelling and stabilization, the number of peptide
drugs reaching the market is very modest (28 since 2000).2 Hence, it is imperative to find new
methods of stabilizing peptides and modulating their pharmacokinetic properties to access their
high therapeutic potential.

3.3

Proteolytic stability of peptides containing α,β-dehydroamino acids
In the late 1970’s, Stammer et al. explored the role of trisubstituted dehydroamino acids in

the stability of enkephalin analogues. They synthesized a pentapeptide Z-Gly-Gly-Phe-ΔZPhe-AlaOH, and showed that it was very stable to the enzymes chymotrypsin and thermolysin even after
30 hours, whereas the saturated peptide Z-Gly-Gly-Phe-Phe-Ala-OH rapidly hydrolyzed. 26
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Motivated by this result, they synthesized the enkephalin analogue Tyr-D-Ala-Gly-ΔZPhe-MetNH2 (ED50 = 3.3 x 109 M) which was five times more active in paralyzing stimulated pig-ileum
than the parent peptide Tyr-D-Ala-Gly-Phe-Met-NH2 (ED50 = 1.7 x 108 M), and was essentially
unhydrolyzed after 30 hours of treatment with chymotrypsin. 27 Similarly, the ΔZLeu5 analogue
(Tyr-D-Ala-Gly-Phe-ΔZLeu-OH) of Tyr-D-Ala-Gly-Phe-Leu-OH was active towards the  opioid
receptor and more stable to enzymatic decomposition than its saturated parent pentapeptide.
In early 1980’s, Stammer and co-workers synthesized three analogues of the vasodilator
peptide bradykinin (Arg1-Pro2-Pro3-Gly4-Phe5-Ser6-Pro7-Phe8-Arg9). One of the unsaturated
analogues [ΔZPhe5]BK (Arg1-Pro2-Pro3-Gly4-ΔZPhe5-Ser6-Pro7-Phe8-Arg9) was found to be more
potent than bradykinin at lowering the blood pressure of rats after intravenous injection and was
also resistant to enzymatic degradation. 28
As α,β-dehydroamino-acid-containing peptides have shown considerable proteolytic
stability combined with static or enhanced biological activity, they have a huge potential to yield
therapeutic peptides which could reach the market.

3.4

Proteolytic stability of β-hairpins containing a bulky α,β-dehydroamino acid in the turn
As described in Chapter 2, we synthesized six bulky α,β-dehydroamino-acid-containing

analogues of the Waters’ β-hairpin by substituting either the i+1 or i+2 residue of the β-turn region
with ΔVal/ΔEnv (Figure 3.2). It has been reported by Waters and co-workers that well-folded βhairpin peptides are more resistant to enzymatic degradation when compared to less-folded βhairpins.29 Pronase E is a mixture of about 10 different proteases that is obtained from the K-1
strain of Streptomyces griseus and cleaves nearly all peptide bonds. It contains five serine-type
proteases, two Zn2+ endopeptidases, two Zn2+ leucine aminopeptidases, and one Zn2+
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carboxypeptidase. Hence, it has no preference for a cleavage site and is the most aggressive
mixture of proteases commercially available. 30
We decided to use the Pronase E mixture to test the proteolytic stability of our peptides. This
highly active mixture should be able to cleave peptides non-specifically, providing a very rigorous
proteolytic test for the enzymatic stability of our β-hairpins. We utilized the proteolysis protocols
developed previously by Seebach et al.31

Figure 3.2. Model β-hairpins and their ΔAA-containing analogues.
Pronase E from Streptomyces griseus (EC 3.4.24.31) was purchased from EMD Millipore.
This mixture of enzymes was dissolved in 1X PBS buffer (10 mM sodium phosphate, 137 mM
NaCl, 2.7 mM KCl buffer, pH 7.4) at a concentration of 0.128 mg/mL. Then, solutions of each
peptide (153a, 152aa, 152ab, 152ba, and 152bb) in 1X PBS buffer (0.10 mM, 1.5 mL) at 37 °C
were treated with an aliquot (5 µL) of the Pronase E solution. Aliquots (50 L) were removed after
0, 30, 60, 90, 150, 210, 270, and 360 min. The aliquots were quenched with 25% v/v glacial acetic
acid (10 L), diluted to 75 µL with 1X PBS buffer, and analyzed by HPLC (Phenomenex Jupiter
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C18, 5 m particle size, 300 Å pore size, 4.6  250 mm, 40 L injection volume, 10%–60%
CH3CN in H2O gradient over 50 min, then 95% CH3CN in H2O for 10 min, flow rate: 1 mL/min).
Substitution of the Asn at i+1 of 153a with either ΔVal or ΔEnv markedly improved the
proteolytic stabilities of the β-hairpins 152aa and 152ab respectively (Figure 3.3). They were ca.
6–7 times more resistant to proteolysis than the parent peptide 153a containing all natural Lresidues. ΔVal-containing analogue 152aa was found to be slightly more stable than the ΔEnv
analogue 152ab.

Figure 3.3. Proteolysis plot of Waters’ β-hairpin 153a and its i+1 analogues 152aa and 152ab.
Substitution of the i+2 (Gly) with the ΔAAs resulted in a more modest stabilizing effect on
β-hairpins 152ba and 152bb (Figure. 3.4). Nevertheless, these analogues were ca. 3 times more
stable when compared to the parent peptide 153a and corroborated our hypothesis that the
incorporation of a ΔAA in the turn region could impart enzymatic stability to β-hairpins without
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destabilizing the secondary structure. The beneficial impact of both the bulky ΔAAs (ΔVal or
ΔEnv) at the i+2 position was essentially identical within experimental error.

Figure 3.4. Proteolysis plot of Waters’ β-hairpin 153a and its i+1 analogues 153ba and 153bb.
Similarly, the D-Pro and ΔAA-containing β-hairpins (152ca and 152cb) were subjected to
proteolysis with Pronase E. These peptides necessitated a higher concentration of the enzyme
mixture, as the D-Pro residue also contributes to the stability of these peptides. Hence, we used
higher concentrations of the Pronase E to digest the peptides on a reasonable time-scale. This
mixture of enzymes was dissolved in 1X PBS buffer (10 mM sodium phosphate, 137 mM NaCl,
2.7 mM KCl buffer, pH 7.4) at a concentration of 0.362 mg/mL. Then, solutions of each peptide
(153b, 152ca, and 152cb) in 1X PBS buffer (0.40 mM, 1.5 mL) at 37 °C were treated with an
aliquot (10 µL) of the Pronase E solution. Aliquots (50 L) were removed after 0, 30, 60, 90, 150,
210, 270, and 360 min. The aliquots were quenched with glacial acetic acid (10 L), diluted to 75
µL with 1X PBS buffer, and analyzed by HPLC (Phenomenex Jupiter C18, 5 m particle size, 300
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Å pore size, 4.6  250 mm, 40 L injection volume, 10%–60% CH3CN in H2O gradient over 50
min, then 95% CH3CN in H2O for 10 min, flow rate: 1 mL/min).
Here, the pairing of ΔVal or ΔEnv at the i+2 position with D-Pro at i+1 improved the
proteolytic resistance of the already enzymatically stable β-hairpin 153b (Figure 3.5.). However,
the stabilizing effect of ΔVal was larger than ΔEnv and considerably evident in this case. Peptide
153ca was ca. 2.5 times more stable to proteolysis than 153b, whereas 153cb was ca. 1.5 times
more stable than the original peptide. Our results demonstrate that the incorporation of a bulky
ΔAA in a peptide containing a D-amino acid can synergistically increase the resistance of the
peptide to enzymatic degradation. Hence, such a combination can be useful in the design of novel
peptides with enhanced proteolytic stability and minimal destabilization of secondary structures.

Figure 3.5. Proteolysis plot of Waters’ β-hairpin 153b and its i+1 analogues 152ca and 152cb.
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Analytical HPLC traces of β-hairpins 153 and their most proteolytically stable ΔAA–
containing analogues are shown below (Figures 3.6–3.9).

Figure 3.6. Analytical HPLC traces (monitored at 220 nm) for peptide 153a (0.10 mM) after
incubation in Pronase E for up to 360 min.

Figure 3.7. Analytical HPLC traces (monitored at 220 nm) for peptide 152aa (0.10 mM) after
incubation in Pronase E for up to 360 min.
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Figure 3.8. Analytical HPLC traces (monitored at 220 nm) for peptide 153b (0.40 mM) after
incubation in Pronase E for up to 360 min.

Figure 3.9. Analytical HPLC traces (monitored at 220 nm) for peptide 152ca (0.40 mM) after
incubation in Pronase E for up to 360 min.
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3.5

One-dimensional and two-dimensional NMR spectroscopy to study the conformations
of α,β-dehydroamino acid containing β-hairpins
Advancements in NMR methodology in the past few decades have made it possible to

determine the three-dimensional structures of small proteins or peptides in solution. With the
increase in magnetic field strength and subsequent higher resolution of 1D and 2D spectra, NMR
sensitivity improved significantly to study peptides or proteins at millimolar concentrations. A
detailed NMR study can reveal important conformational features of peptides and proteins. Peptide
secondary structures induce unique chemical shifts for certain amino acids. It has been shown that
a strong relationship exists between CαH 1H NMR chemical shifts and protein secondary structures
for all the naturally occurring 20 amino acids. 32
The chemical shift perturbations to Cα protons in α-helices, turns and β-sheets have been
widely studied, and provide valuable insights into the folding patterns of peptides. When compared
to the random coil (0% folded) Cα proton chemical shift values, there is an upfield shift in Cα
protons in α-helices and turns, whereas Cα protons are shifted downfield in β-sheets.33 There are
alternating hydrogen-bonded residues in the strands of β-hairpins, which leads to i, i+2 periodicity.
Sharman et al. observed that Cα protons of the residues in β-hairpin strands are exposed to two
different chemical environments and hence, they classified these protons into Hin (CαH facing the
opposite strand) and Hout (CαH away from the opposite strand or outward into the solvent).34
Moreover, Hin protons are part of residues that are not involved in hydrogen bonding, whereas Hout
protons belong to residues that are engaged in hydrogen bonding. They observed that there are
larger chemical shift deviations from the random coil values for Hin than for Hout. This observation
can be attributed to the electrostatic and anisotropic effect of the carbonyl group on the residues of
the opposite strand. They postulated that CαH chemical shift deviations in well-folded β-hairpins
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were higher because of the proximity of the two strands and smaller H-bonding distances between
them. Further structural elucidation can be done by NOESY and ROESY studies to investigate
the spatial interactions between the two strands. Hence, 1D and 2D NMR studies are very
informative and crucial in the determination of β-hairpin folding.
We performed 1D and 2D NMR studies on all the α,β-dehydroamino-acid-containing βhairpins we synthesized. Peptide solutions were prepared in 20 mM sodium phosphate buffer, pH
7, and peptide concentrations were determined spectroscopically based on tryptophan absorbance
at 280 nm in 6 M guanidine hydrochloride (Trp 280 = 5690 M–1cm–1). NMR samples of monomeric
152aa–152cb were prepared (1–3.5 mM peptide) in D2O (10% v/v D2O/H2O) buffered to pD 3.9
with 5000 M NaOAc-d3/CD3COOD buffer. Sodium 2,2-dimethyl-2-silapentane-5-sulfonate
(DSS) was used as an internal chemical shift reference and was set to 0 ppm. Water suppression
was achieved by an excitation sculpting (ES) sequence. 2D zTOCSY and ROESY-AD experiments
were performed on all the samples and enabled us to assign all the amide and CαH protons
unambiguously.
As discussed earlier in this section, we also observed downfield chemical shifts relative to
the random coil values for all CαH protons in the two strands. It is noteworthy to mention that the
CαH protons of the residues not involved in H-bonding shifted further downfield which is in
agreement with the literature reports. The CαH protons of the two turn residues are shifted upfield
and the C terminus also shows upfield shifts because of fraying at the ends of the strands. The
trends for CαH chemical shifts of all the β-hairpins we synthesized are shown below (Figures
3.10–3.17). Since we synthesized random coils 168 for peptides 153a and 152aa, their chemical
shifts are compared to their random coil shift values, whereas we used the random coil references
reported in the literature for the rest of the peptides (Figure 3.10).35
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Figure 3.10. Random coils (168).

Figure 3.11. Hα chemical shift differences between the residues in 153a and the corresponding
random coil 7-mers 168a and 168b.
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Figure 3.12. Hα chemical shift differences between the residues in 153b and the random coil
values obtained from Wüthrich, K. NMR of Proteins and Nucleic Acids, Wiley: New York (1986).

Figure 3.13. Hα chemical shift differences between the residues in 152aa and the corresponding
random coil 7-mers 168c and 168d.
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Figure 3.14. Hα chemical shift differences between the residues in 152ab and the random coil
values obtained from Wüthrich, K. NMR of Proteins and Nucleic Acids, Wiley: New York (1986).

Figure 3.15. Hα chemical shift differences between the residues in 152ba and the random coil
values obtained from Wüthrich, K. NMR of Proteins and Nucleic Acids, Wiley: New York (1986).
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Figure 3.16. Hα chemical shift differences between the residues in 152bb and the random coil
values obtained from Wüthrich, K. NMR of Proteins and Nucleic Acids, Wiley: New York (1986).

Figure 3.17. Hα chemical shift differences between the residues in 153ca and the random coil
values obtained from Wüthrich, K. NMR of Proteins and Nucleic Acids, Wiley: New York (1986).
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Figure 3.18. Hα chemical shift differences between the residues in 153cb and the random coil
values obtained from Wüthrich, K. NMR of Proteins and Nucleic Acids, Wiley: New York (1986).
It is evident from Figures 3.11–3.18 that the Hα chemical shifts are shifted significantly
downfield (i.e.  0.2 ppm) when compared to the random coil values and that α,β-dehydroaminoacid-containing peptides are in fact forming a significant population of β-hairpin structures in
solution.
Multiple cross-strand NOEs were observed in all the peptides, which further corroborates
that the two opposite strands are in close proximity. These NOE peaks are characteristic features
of β-hairpins or β-sheets. Except for 152ab and 152bb, all the peptides exhibited one set of welldefined spin systems suggesting the existence of a highly populated single low-energy
conformation. This can also be attributed to rapid equilibration between multiple conformations.
Extra spin systems were detected in homogeneous solutions of peptides 152ab and 152bb, which
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can be explained by the occurrence of two or more conformations that interconvert slowly on the
NMR time scale (Figure 3.19).

Figure 3.19. Multiple spin systems in the TOCSY spectra of 152ab.
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The tables listing major NOE peaks of peptides 152,153 & 167b are given below (Tables 3.1–3.9).
Table 3.1. Ac-R-W-V-E-V-N-G-O-K-I-L-Q-NH2 (153a).
Res I
2Trp H2,4
2Trp H7
2Trp α
2Trp β
2Trp H6
2Trp H2,7
2Trp H2
2Trp H6
2Trp β, H7
2Trp α
1Arg α
1Arg β
4Glu H
2Trp H6,7
2Trp H2
5Val γ
5Val H
2Trp H2,6,7
2Trp H7
5Val γ

Res II
11Leu δ
11Leu δ
11Leu δ
11Leu δ
11Leu γ
11Leu α
11Leu β
11Leu β
11Leu β
11Leu α
11Leu δ
12Gln H
10Ile γ
10Ile α
10Ile α, γ
8Orn H
8Orn H
9Lys γ
9Lys α
6Asn δ

Peak
S
M
M
W
M
M
M
W
S
S
M
W
S
S
M
M
S
S
W
S

Table 3.2. Ac-R-W-V-E-V-p-G-O-K-I-L-Q-NH2 (153b).
Res I
2Trp H4
2Trp α, H2
2Trp H1,7
2Trp α
2Trp H1,4
2Trp H1,5
2Arg α
2Trp H2
2Trp H4
2Trp H1,4
2Trp α
2Trp H5
2Trp H1
2Trp H4
4Glu γ
6D-Pro α
5Val H
1Arg δ
2Trp H2
5Val γ

Res II
11Leu α
11Leu α
11Leu δ
11Leu δ
11Leu δ
11Leu γ
11Leu δ
9Lys γ
9Lys γ, δ
9Lys β
10Ile H
10Ile α
10Ile α
10Ile α
8Orn H
8Orn H
8Orn H
12Gln α
12Gln γ
6D-Pro δ

Peak
M
S
S
W
W
M
M
W
M
S
S
S
M
W
M
M
M
M
M
S
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Table 3.3. Ac-R-W-V-E-V-∆Val-G-O-K-I-L-Q-NH2 (152aa).
Res I
2Trp H1,4
2Trp H7
2Trp H2
2Trp α, β
2Trp H2,5
2Trp H2,4
2Trp α
2Trp H2
1Arg α
4Glu β
2Trp H2,5
2Trp H4d
2Trp H4
2Trp H4
2Trp H4
2Trp H2
2Trp H5
2Trp H4
5Val H
2Trp H2
1Arg H
6∆Val γ

Res II
11Leu δ
11Leu δ
11Leu δ
11Leu δ
11Leu γ
11Leu α
11Leu α
11Leu β
11Leu δ
11Leu δ
9Lys β
9Lys δ
9Lys γ
9Lys β
10Ile α
10Ile α
10Ile α
10Ile γ
8Orn H
12Gln γ
12Gln β
5Val γ

Peak
W
M
S
M
M
M
S
W
M
M
M
M
W
S
M
W
S
S
S
W
W
S

Table 3.4. Ac-R-W-V-E-V-∆Env-G-O-K-I-L-Q-NH2 (152ab).
Res I
2Trp H2
2Trp α, H4,5
2Trp H7
2Trp H2,5
2Trp H4,7
2Trp α
2Trp H2
2Trp H4
2Trp H5
2Trp H2
2Trp H2
9Lys β, γ, δ
9Lys γ, ε
2Trp H5
2Trp H4
8Orn β
6∆Env δ
1Arg δ
1Arg α

Res II
11Leu δ
11Leu δ
11Leu δ
11Leu γ
11Leu γ
11Leu α
10Leu α
11Leu α
10Ile α
10Ile α
9Lys β
2Trp H4
2Trp H2
9Lys β
12Gln γ
5Val H
5Val α
12Gln ε
11Leu δ

Peak
S
W
M
M
W
S
W
M
M
W
M
S
W
M
S
S
W
S
S
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Table 3.5. Ac-R-W-V-E-V-N-∆Val-O-K-I-L-Q-NH2 (152ba).
Res I
1Arg ε
1Arg ε
2Trp H2
2Trp H1,7
2Trp H2,4
2Trp β
2Trp α
2Trp α
2Trp H7
2Trp H2
2Trp H7
2Trp H2
2Trp H7
2Trp H2
2Trp H6
2Trp H2,7
2Trp H7
5Val H
4Glu γ
4Glu γ

Res II
12Gln γ
10Ile γ
10Ile γ
11Leu δ
11Leu δ
11Leu δ
11Leu δ
11Leu α
9Lys γ
9Lys γ
11Leu α
11Leu α
10Ile α
10Ile α
10Ile α
11Leu β
11Leu δ
9Orn H
7∆Val H
8Orn H

Peak
W
M
M
W
M
W
M
S
S
W
S
M
M
W
S
S
S
M
S
S

Table 3.6. Ac-R-W-V-E-V-N-∆Env-O-K-I-L-Q-NH2 (152bb).
-Res I
2Trp H2,7
2Trp H1,4
2Trp α
2Trp H7
2Trp H5
2Trp α
2Trp H7
1Arg H
2Trp H2
2Trp H7
2Trp H2
2Trp H7
1Arg ε
2Trp H2
1Arg ε
5Val H
11Leu α
6Asn δ

Res II
11Leu δ
11Leu δ
11Leu δ
11Leu β
11Leu γ
11Leu α
11Leu α
11Leu δ
9Lys β
9Lys β
9Lys δ
9Lys γ
9Lys β
4Glu γ
10Ile γ
8Orn H
2Trp H2
5Val γ

Peak
M
W
S
S
W
S
M
M
M
S
W
S
M
S
W
M
W
S
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Table 3.7. Ac-R-W-V-E-V-p-∆Val-O-K-I-L-Q-NH2 (152ca).
Res I
2Trp H1,4,7
2Trp H6,α
2Trp H2
2Trp H2,6
2Trp H2,7
2Trp α
2Trp H7,β
1Arg H,α
2Trp H6
2Trp H7
2Trp H2
2Trp H7
2Trp H7,β
2Trp H6
4Glu H
4GluH
1Arg H
2Trp α
5Val H
5Val γ

Res II
11Leu δ
11Leu δ
11Leu δ
11Leu γ
11Leu α
11Leu α
11Leu β
11Leu δ
10Ile α
10Ile H
10Ile γ
9Lys β
9Lys γ
9Lys δ
9Lys α
10Ile γ
12Gln H
12Gln H
8Orn H
6D-Pro δ

Peak
M
W
S
W
W
S
S
M
S
M
W
S
M
W
S
S
S
W
S
S

Table 3.8. Ac-R-W-V-E-V-p-∆Env-O-K-I-L-Q-NH2 (152cb).
Res I
2Trp H1,4
2Trp H2,7, α
2Trp α
2Trp H4, α
2Trp H2
2Trp H4
1Arg α
1Arg H
2Trp H4
2Trp H4
2Trp H2
2Trp H2,5
4Trp H2
1Trp H4
4Glu H
5Val H
2Trp H5
2Trp H2
2Trp H4
4Glu H
6D-Pro δ
5Val γ

Res II
11Leu δ
11Leu δ
11Leu δ
11Leu α
11Leu α
11Leu β
11Leu δ
12Gln β
12Gln α
9Lys β
9Lys β
9Lys γ
9Lys δ
9Lys δ
9Lys α
8Orn H
10Ile α
10Ile α
10Ile γ
10Ile γ
7∆Env
6D-Pro δ

Peak
W
M
M
S
M
M
W
W
W
S
M
W
W
M
S
S
S
W
M
S
S
S
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Table 3.9. c[Ac-Cys-R-W-V-E-V-∆Val-G-O-K-I-L-Q-Cys-NH2] (167b).
Res I
2Trp α
2Trp H1,2,4
2Trp H5,7
2Trp H4,2
2Trp H4
2Trp H2
2Trp α
2Trp H5
2Trp H2
1Arg α
2Trp H2
2Trp H4
2Trp H5
2Trp H2
2Trp H2
2Trp H2
2Trp H5
5Val H
6∆Val γ

Res II
11Leu δ
11Leu δ
11Leu δ
11Leu γ
11Leu α
11Leu α
11Leu α
11Leu H
11Leu H
11Leu δ
9Lys β
9Lys β
9Lys β
9Lys ε
9Lys δ
10Ile α
10Ile α
8Orn H
6Val γ

Peak
M
M
W
W
W
S
S
W
M
M
S
W
M
W
M
M
S
S
S

3.5.1 Determination of the β-hairpin population in solution (percent folded)
Along with the qualitative estimation of folding, 1H NMR chemical shifts have also been
used reliably to compute the percent folded in solution.29, 36 The percent folded state was
determined using two methods.
First, the Hα chemical shifts of residues that form cross-strand hydrogen bonds in peptides
152aa and 153a were compared to the corresponding Hα chemical shifts in random coil 7-mers
168 representing the unfolded structures (and Hα chemical shifts in cyclic controls 167 (Section
2.7) representing the fully folded structures (). The Hα chemical shifts of residues in peptides
153a and 152aa were designated as obs. The percent folded at each residue was determined by
Equation (i):
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Percent Folded = [(𝛅obs- 𝛅o)/𝛅100- 𝛅o)] X 100 %

(i)

The overall percent folded was calculated by averaging the percent folded values for
residues Val3, Val5, Orn8, and Ile10, each of which are involved in cross-strand hydrogen bonds
(Table 3.10 and Table 3.11).
Table 3.10. Percent folded state of Ac-R-W-V-E-V-∆Val-G-O-K-I-L-Q-NH2 (152aa).
Amino
Acids

152aa

167b

Random
Coil

%
Folded

Average
% Folded

Standard
Error

Val 3

4.534

4.608

4.009

87.64

89.99

2.0

Val 5

4.385

4.397

4.151

95.12

Orn 8

4.666

4.697

4.354

90.96

K

Std. error

Ile 10

4.635

4.715

4.134

86.23

9.0

2.0

ΔG(kcal/mol)

Std. error (kcal/mol)

–1.30

0.13

Table 3.11. Percent folded state of Ac-R-W-V-E-V-N-G-O-K-I-L-Q-NH2 (153a).
Amino
Acids

153a

167a

Random
Coil

%
Folded

Average %
Folded

Standard
Error

Val 3

4.447

4.586

4.003

76.16

77.30

2.0

Val 5

4.222

4.249

4.090

83.02

Orn 8

4.620

4.696

4.364

77.11

K

Std error

Ile 10

4.564

4.717

4.152

72.92

3.4

0.4

ΔG (kcal/mol)

Std. error (kcal/mol)

–0.73
0.07
This method showed that peptide 152aa and 153a existed in ca. 90% and 77% folded states
respectively.
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The overall percent folded was also determined by measuring the differences in chemical
shift of the two diastereotopic H signals from the glycine residues in 153a and 152aa. This was
done using equation (ii):
Percent Folded = (∆𝜹Observed/100) X 100 %

(ii)

where ∆𝛿 Observed is the difference between the two diastereotopic glycine Hα chemical shifts
observed for 153a or 152aa and 100 is the difference between the two diastereotopic glycine Hα
chemical shifts of the corresponding cyclic peptide 167a or 167b (Table 3.12 and 3.13).
Table 3.12. Percent folded state of Ac-R-W-V-E-V-∆Val-G-O-K-I-L-Q-NH2 (152aa).
Peptide
Cyclic peptide
(167b)

Gly Hαa

Gly Hαb

Glycine Splitting

4.1322

3.7217

0.4105

152aa

4.1141

3.7296

0.3845 (∆𝛿 Observed)

K = 14.79

ΔG (kcal/mol)

–1.60

(∆𝛿 100)

% Folded
93.7

Table 3.13. Percent folded state of Ac-R-W-V-E-V-N-G-O-K-I-L-Q-NH2 (153a).
Peptide
Cyclic peptide
(167a)

Gly Hαa

Gly Hαb

Glycine Splitting

4.1354

3.6865

0.4489

153a

4.0941

3.7674

0.3267 (∆𝛿 Observed)

K = 2.67

ΔG (kcal/mol)

–0.58

(∆𝛿 100)

% Folded
72.8

This method also supports our previous results that the α,β-dehydroamino acid containing
peptide 152aa is forming a β-hairpin in solution. Peptide 152aa showed improved folding (ca.
94%) than the parent peptide 153a (ca. 73%) corroborating our hypothesis that ΔAAs could induce
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β-turns. In terms of Gibbs free energy for folding, ΔVal incorporation at the i+1 position in a βturn favors β-hairpin formation or folding by ca. 0.6–1.0 kcal/mol.

3.6

Circular dichroism spectroscopy of α,β-dehydroamino acid containing β-hairpins
The NMR observations are further supported by the CD spectra of 153a, 153b, 152aa and

152ca. They all exhibited the characteristic β-sheet or β-hairpin minima at 215 nm as shown below
(Figure 3.20–3.21).

Figure 3.20. CD wavelength scan for peptides 153a and 152aa at 25 °C.

Figure 3.21. CD wavelength scan for peptides 153b and 152ca at 25 °C.
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3.7

NOE-restrained structural calculations and peptide ensembles
In order to support our experimental observations, we performed NOE-restrained structural

calculations using the simulated annealing algorithm CYANA. This could provide further insights
pertaining to the peptide structures in solution. We generated conformational ensembles of all the
peptides by using unambiguous cross-strand ROESY peaks, which are presented in Tables 3.1–3.8
for each peptide. We used four hydrogen bonding restraints for the residues that are engaged in Hbonding across the opposite strands, but were unable to use any dihedral angle restraints because
of insufficient secondary chemical shift data available for several nonstandard residues in our
peptides.
We selected and superimposed the 10 lowest-energy conformations determined by the
CYANA objective function, from 100 preliminary conformations obtained. All the ensembles of
the 10 best conformations showed the expected hydrogen bonding pattern along the strands,
dihedral angles and the overall secondary structure that is in good agreement with the β-hairpin
motif. Conformational similarities between parent peptide 153a and the β-hairpin containing ΔVal
at i+1 (152aa) could be seen clearly from their ensembles (Figure 3.22).

Figure 3.22. Solution-phase structures of 153a (left) and 152aa (right) as calculated by NOErestrained molecular dynamics. Side chains have been removed for clarity.
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A qualitative examination of the simulated structures indicated that β-hairpins containing
ΔVal were more stable or rigid than the ones containing ΔEnv. It is rational to see less rigid
conformations for 152bb and 152cb as multiple spin systems were observed in their 2D NMR
spectra. This is also evident from their relatively larger backbone RMSD values obtained from the
structural calculations.
Structural ensembles of all the β-hairpin peptides are shown below in Figures 3.23–3.29.
RMSD values were calculated based on the backbone atoms and only include residues 3–10 to
avoid the impact of fraying of the ends of the strands where less NOEs were found. Graphic
representations were generated using VMD. 37

Position Res.
i

Val

i+1

Asn

i+2

Gly

i+3

Orn

Backbone RMSD (Å):
0.180 ± 0.008

Figure 3.23. Solution structure of the peptide 153a.
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Position Res.
i

Val

i+1

D-Pro

i+2

Gly

i+3

Orn

Backbone RMSD (Å):
0.396 ± 0.143

Figure 3.24. Solution structure of the peptide 153b.

Position AA
i

Val

i+1

∆Val

i+2

Gly

i+3

Orn

Backbone RMSD (Å):
0.128 ± 0.037

Figure 3.25. Solution structure of the peptide 152aa.
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Position AA
i

Val

i+1

∆Env

i+2

Gly

i+3

Orn

Backbone RMSD (Å):
0.335 ± 0.075
Figure 3.26. Solution structure of the peptide 152ab.

Position Res.
i

Val

i+1

Asn

i+2

∆Val

i+3

Orn

Backbone RMSD (Å)
0.256 ± 0.120
Figure 3.27. Solution structure of the peptide 152ba.

82

Position Res.
i

Val

i+1

Asn

i+2

∆Env

i+3

Orn

Backbone RMSD (Å)
0.601 ± 0.113
Figure 3.28. Solution structure of the peptide 152bb.

Position AA
i

Val

i+1

D-Pro

i+2

∆Val

i+3

Orn

Backbone RMSD (Å):
0.262 ± 0.184

Figure 3.29. Solution structure of the peptide 152ca.
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Position

AA

i

Val

i+1

D-Pro

i+2

∆Env

i+3

Orn

Backbone RMSD (Å):
0.312 ± 0.108

Figure 3.30. Solution structure of the peptide 152cb.
We relied on cross-strand peaks for structural calculations because of their high quality
signals caused by the proximity of the strands, and they are listed in Tables 3.1–3.9 along with
their relative intensities. The details of the restraints used in the structural constraints are tabulated
below (Table 3.14).
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Table 3.14. Restraints and calculation parameters.

Structure

1

2

152aa

152ab

152ba

152bb

152ca

152cb

32

28

28

31

29

24

29

31

Cross-strand

31

26

28

30

29

22

27

29

Sequential

1

2

0

1

0

2

2

2

Intra-residue

0

0

0

0

0

0

0

0

Strong Intensity

14

8

6

11

9

8

10

12

Medium Intensity

11

14

14

9

9

9

10

9

Weak Intensity

7

6

8

11

11

7

9

10

Hydrogen Bonds

4

4

4

4

4

4

4

4

Dihedral Restraints

0

0

0

0

0

0

0

0

0.18 ±

0.40 ±

0.13 ±

0.34 ±

0.26 ±

0.60 ±

0.26 ±

0.31 ±

0.01

0.14

0.04

0.08

0.12

0.11

0.18

0.11

0.57 ±

0.74 ±

0.54 ±

0.67 ±

0.72 ±

1.32 ±

0.86 ±

0.77 ±

0.08

0.11

0.08

0.09

0.17

0.34

0.25

0.26

Conformational
restraints
Total Distance
Restraints

RMSD from Ideality:
Backbone (Å)
All atoms (Å)

3.8

Conclusions
We have established with strong evidence that incorporation of a bulky α,β-dehydroamino

acid at either the i+1 or the i+2 positon in the turn region of a known β-hairpin can impart
considerable proteolytic stability and enhance folding. Proteolysis experiments, NMR studies and
structural calculation results suggest that backbone rigidification and increased folding may be
partly responsible for proteolytic stability. ΔVal-containing β-hairpins are either more stable or
equally stable to proteolysis than their ΔEnv-containing analogues, and this can be in part
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attributed to their more rigid conformations in solution. The β-hairpin 152aa with ΔVal at the i+1
position in the turn was found to be more folded than the parent peptide 153a, with its folding
favored by ca. 0.6–1.0 kcal/mol. Since folded peptides and proteins are less susceptible to
enzymatic decomposition, we can confidently propose that a part of the significantly enhanced
proteolytic stability of peptide 152aa (ca. 7 times more stable than 153a) is due to its high folded
population. Substitution of the i+1 residue with ΔEnv led to multiple conformations with a slightly
smaller enhancement in proteolytic resistance, whereas as the i+2 substitution with either ΔVal or
ΔEnv was less favorable for both proteolytic resistance and folding. Nevertheless, all the bulky
ΔAA-containing peptides were more stable to proteolysis than the parent peptide 153a and showed
β-hairpin formation. We have also demonstrated that the synergistic pairing of D-Pro (i+1) and a
bulky ΔAA (i+2) can improve the proteolytic resistance to enzymatic degradation.
Though it is still unclear if the incorporation of a ΔAA stabilizes the folded states or
destabilizes the unfolded states, we propose that a bulky ΔAA can destabilize several unfolded or
random coil conformations of peptides 152 due to their inherently high A1,3 strain, thereby shifting
the equilibrium towards folded conformations. Since the insertion of a bulky α,β-dehydroamino
acid into the turn regions of β-hairpins can promote proteolytic stability without perturbing the
secondary structures, we believe that this novel approach is very promising in stabilizing bioactive
turn-containing peptides for therapeutic use.

3.9
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PROGRESS TOWARDS THE TOTAL SYNTHESIS OF YAKU’AMIDE A

4.1

Isolation, structure, and biological activity
Several biologically active natural peptides with unprecedented chemical structures have

been isolated from marine organisms. Marine sponges are one of the richest sources of secondary
metabolites that are pharmacologically active. In order to survive in the harsh ocean environment
and evade predators, these marine invertebrates produce highly potent toxins. Researchers have
isolated several types of polyketides and nonribosomal peptides from marine sponges. 1 In 2010,
Matsunaga and co-workers isolated the acyclic peptides yaku’amide A and B from the deep sea
sponge Ceratopsion sp. obtained at a depth of 150 m at Yakushinsone in the East China Sea, which
exhibited potent cytotoxicity (Figure 4.1).2

Figure 4.1. Initially proposed structure of Yaku’amide A and B.
These acyclic peptides (169 and 170) contain a variety of β-hydroxyamino acid (β-OHAA)
and α,β-dehydroamino acid (ΔAA) residues. They exhibited three β-OHAA residues including (2S,
3R)-hydroxyisoleucine (OHIle) and D- and L-hydroxyvaline (OHVal) along with four ΔAA
residues including Z-ΔIle, E-ΔIle, and ΔVal. Z-ΔIle is unique, as it has never been seen in natural
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products before.3 Moreover, they have unique C-terminal and N-terminal groups, which were also
unprecedented.
Yaku’amide A and B were tested against P388 murine leukemia cells (JCRB17), and found
to be highly cytotoxic with low IC50 values of 14 and 4 ng/mL, respectively. Notably, the
cytotoxicity profile of yaku’amide A towards a panel of 39 human cancer cell lines (JFCR39)
including various types of human cancers was found to be unique when compared to 38 anticancer
drugs that have been examined in this panel of cell lines.4 Hence, it is very significant to investigate
and discover the biological target of yaku’amide A for the development of novel anticancer agents.
4.2

Total synthesis of Yaku’amide A by Inoue and co-workers
Since yaku’amide A has a complex chemical structure with several β-OHAA and

asymmetric ΔAA, its total synthesis is very challenging. However, Inoue et al. reported the first
total synthesis of yaku’amide A (169) in 2013. They synthesized β-OHAA residues (2S, 3R)hydroxyisoleucine (OHIle) and D- and L-hydroxyvaline (OHVal) via previously known
protocols. 5 Both the isomers of β-OHVal were constructed based upon the method developed by
Lubell and co-workers, whereas (2S, 3R)-OHIle was prepared according to the protocol developed
by Guanti et al.6
The synthesis of Z-ΔIle and E-ΔIle was more challenging. The previously reported methods
for the construction of E-ΔIle were reliable, but tedious.7 Inoue and co-workers developed a Cucatalyzed cross-coupling reaction for the synthesis of the Z-ΔIle and E-ΔIle as reported in Chapter
1.8
In 2015, they revised the structures of yaku’amide A and B after extensive investigations
and corrected the configurations of the two Val residues near the C-terminal and both the β-OHVal
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residues (Figure 4.2). Their total synthesis consists of 86 total steps and a 25-step longest linear
sequence.

Figure 4.2. Revised structure of Yaku’amide A and B.
4.3

Retrosynthetic analysis of yaku’amide A
Castle and Ma developed more efficient methods for the syntheses of the three β-

hydroxyamino acids (β-OHAAs) and asymmetric ΔAAs seen in yaku’amide A. β-OHAAs were
synthesized via a base-free OsO4-catalyzed aminohydroxylation protocol and stereoselective antidehydration of β -OHIle afforded the E- and Z-ΔIle residues. 9 Our retrosynthetic analysis of
yaku’amide A (17a) is shown in Scheme 4.1. Yaku’amide A (17a) can be disconnected at the two
amides as indicated into three important intermediates. Left-hand pentapeptide 173 and right-hand
nonapeptide 174 can be further deconstructed to give simpler building blocks. The synthesis of Eand Z-ΔIle residues is challenging as the activation of the carboxyl functional group of an
asymmetric Δ AA can cause isomerization via azlactone formation, thereby scrambling the
stereochemistry. Previous works on E- and Z-ΔIle construction report compulsory backbone
amide protection to prevent isomerization. Hence, a one-pot sequence including stereoselective
anti-dehydration mediated by Martin Sulfurane, azide reduction, and O→N acyl transfer was
devised to access the components containing E- and Z-ΔIle residues.
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(2S, 3R)-OHIle (181) was synthesized via base-free OsO4-catalyzed aminohydroxylation with
a chiral nitrogen source10 because of the lack of a catalytic enantioselective aminohydroxylation
method for its synthesis. This protocol is considerably useful as the other diastereomer (2R, 3S)OHIle can be used to synthesize Z-ΔIle.

Scheme 4.1. Retrosynthetic route of Yaku’amide A (17a).
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The N-terminal acyl group 172 would be prepared via Myers’ asymmetric alkylation
followed by a Mukaiyama-type Claisen reaction. This is a more efficient synthetic route to 172
when compared to Inoue’s synthesis of 172.8

4.4

Synthesis of β-OHIle (178 and 182) for the preparation of fragments containing Zand E-ΔIle residues
While working on the solid-phase synthesis of (SPPS) of β-hairpins containing bulky α,β-

dehydroamino acids, I was also engaged in the synthesis of β -OHAAs for yaku’amide A. I
synthesized racemic mixture of β-OHVal 154a via aminohydroxylation protocol developed in
our lab (Scheme 2.2).11 This amine is the precursor to ΔVal, which was required in the synthesis
of both bulky α,β- dehydroamino-acid-containing β-hairpins and yaku’amide A.
Apart from the precursor for ΔVal, I provided both cis- and trans-amines 182 and 178,
which were then later transformed to Z- and E-ΔIle residues respectively. Amines 178 and 182
were synthesized by base-free regioselective aminohydroxylation developed by Ma and Castle
(Scheme 4.2).

Scheme 4.2. Synthesis of racemic amines 182 and 178 by base-free regioselective
aminohydroxylation.
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OsO4-Catalyzed regioselective aminohydroxylation of trans-trisubstituted enoate 194 with
mesyloxycarbamate 158 provided racemic 195 which upon Cbz deprotection provided amine 182.
Similarly, amine 178 was synthesized from cis-trisubstituted enoate 197. These amines 182 and
178 were then utilized by the fellow graduate student Yu Cai to prepare fragments containing Zand E-ΔIle residues (Scheme 4.3).9

Scheme 4.3. Synthesis of tripeptide 207, a subunit of nonapeptide 174.
It is noteworthy that the one-pot stereospecific anti-dehydration mediated by Martin
Sulfurane, azide reduction, and O→N acyl transfer proceeded with excellent diastereoselectivity.
This is a more efficient and convenient method of preparing Z-ΔIle as it does not require amide
backbone protection and is not prone to isomerization.
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Similarly, Yu Cai utilized amines 182 and 178 to incorporate Z- and E-ΔIle residues
respectively in the left-hand pentapeptide 173.

4.5

Synthesis of (2S,3R)-OHIle for left-hand pentapeptide 173
Chiral mesyloxycarbamate 211 was synthesized from benzaldehyde by the 5-step procedure

developed by Lebel et al.10 This chiral nitrogen source was used in the synthesis of a 1:1
diastereomeric mixture of β-OHIle 181 as shown in Scheme 4.4.

Scheme 4.4. Regioselective aminohydroxylation to prepare (2S, 3R)-β-OHIle.
Regioselective aminohydroxylation of trans-enoate 194 with the chiral mesyloxycarbamate
211 yielded a 1:1 mixture of (2S, 3R)-212 and (2R, 3S)-212 (Scheme 4.4). It was not possible to
separate the two diastereomers at this stage, hence they were separated after TES protection of the
tertiary alcohol. Separation was performed by Dr. Castle and undergraduate labmate Blake
Christensen. The diastereomer (2S, 3R)-181 is more polar and eluted later. This was utilized by
Yu Cai in the construction of the left-hand pentapeptide 173, whereas the less polar isomer (2R,
3S)-181 was used in the formation of Z-ΔIle.
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4.6

Synthesis of 172, the N-terminal acyl group (NTA)
Inoue and co-workers elegantly synthesized the NTA (172), but it required 10-steps for them

to accomplish it. We proposed a shorter and more efficient route to access 172. Our synthetic route
to prepare 172 is shown in Scheme 4.5 and was developed by Dr. Castle and graduate student
Zhiwei Ma along with Yu Cai.

Scheme 4.5. Synthesis of the NTA (172).
The chiral amide (1R,2R)-213 was prepared from (1R,2R)-(–)-pseudoephedrine and
propionyl chloride. It was then subjected to Myers’ asymmetric alkylation with 1-iodo-2methylpropane (214) to afford the amide 215 in 78% yield. 12 (S)-2,4-dimethylpentanoic acid (216)
was obtained by acid-catalyzed hydrolysis of the chiral auxiliary in good yield. The chiral acid
216 was subjected to cross-Claisen condensation with the ketene silyl acetal 217 in the presence
of catalytic amounts of InBr3 to yield a β-ketoester.13 This β-ketoester was reduced in one-pot to
give diol 218 in 64% yield from 216. Previous attempts to hydrolyze the methyl β-ketoester to 172
were unsuccessful; hence, it was directly reduced to the diol 218. I prepared about 1.5 g of the diol
218. Even though Inoue et al. reported the oxidation of the diol with AZADO (219), it was very
challenging and not reproducible in our hands. Yu Cai accomplished the oxidation only once in
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good yield, but, he was unable to reproduce it. We tried several different batches of AZADO
(Sigma Aldrich Inc., USA), but we were unsuccessful in obtaining even a few milligrams of the
β-ketoacid 172 again. We contacted Assistant Professor Dr. Hiroaki Itoh from the laboratory of
Professor Dr. Masayuki Inoue for insights on the oxidation of diol 218 and information about their
vendor for AZADO. They also purchased AZADO from Sigma Aldrich. We contacted Sigma
Aldrich and were told that the batch of AZADO was made about 2 years ago. I only obtained NTA
in 43% yield once from the AZADO (purchased in 2015) that was stored under Ar at cold
temperatures, but none of the new batches of AZADO worked successfully. We believe that the
quality of AZADO was bad and hence, the reaction was not reproducible. Going forward, our lab
will synthesize AZADO and use it fresh.

4.7

Synthesis of yaku’amide A (17a)

Scheme 4.6. Synthesis of yaku’amide A (17a).
The tetradecapeptide 219 was treated with HCl solution to remove the Boc and TES
protecting groups, and then coupled with NTA (172) using COMU. Mass spectrometry of the
reaction mixture showed that the coupling was complete. Rough purification by flash
chromatography was performed, followed by RP-HPLC isocratic elution on COSMOSIL-π-NAP
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columns with 50% v/v n-propanol and water (1% acetic acid). Multiple peaks with the correct m/z
were found. The major peak matched an authentic sample of yaku’amide A obtained from Prof.
Inoue, but the quantity of the compound obtained was insufficient for a good 1H NMR.

4.8

Conclusion
Unfortunately, I was unable to obtain a sufficient amount of yaku’amide A (17a) for the 1H

NMR and 13C NMR. The quality of the tetradecapeptide 219 and the challenges in preparing NTA
(172) along with the purification of yaku’amide A hampered my goal to make enough amount of
it to perform NMR studies. It was found that oxidation of the diol 218 requires high-quality
AZADO. Nevertheless, we have successfully performed the final coupling of the unprotected
tetradecapeptide with the NTA (172) and investigated the purification of yaku’amide A, which
will help my colleagues in the lab to successfully synthesize and purify yaku’amide A.

4.9
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EXPERIMENTAL SECTION

5.1

General Experimental Details

N,N-Dimethylformamide and tetrahydrofuran were dried by passage through a solvent drying
system containing cylinders of activated alumina. 1 Other solvents and reagents were purchased
from commercial vendors and used without purification. Flash chromatography was carried out
using 60–230 mesh silica gel. 1H NMR spectra were acquired on a 500 MHz spectrometer with
chloroform (7.27 ppm) as internal reference. Signals are reported as follows: s (singlet), d
(doublet), t (triplet), q (quartet), p (pentet), h (hextet), dd (doublet of doublets), dt (doublet of
triplets), tt (triplet of triplets), qd (quartet of doublets), br s (broad singlet), m (multiplet). Coupling
constants are reported in hertz (Hz). 13C NMR spectra were acquired on a spectrometer operating
at 125 MHz with chloroform (77.23 ppm) as internal reference. Infrared spectra were obtained on
an FT-IR spectrometer. Mass spectral data were obtained using ESI techniques. Circular dichroism
measurements were made with an Aviv 420 Circular Dichroism Spectropolarimeter, using quartz
cuvettes with a path length of 0.1 cm.

1

Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J.
Organometallics 1996, 15, 1518.
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5.2

Experimental procedures and spectral data

5.2.1 Synthesis of Dipeptides 148

Ethyl

2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)-3-

hydroxy-3-methylbutanoate (148aa). A solution of Alloc-Val-OH (155a, 658.3 mg, 3.27 mmol,
1.5 equiv) in DMF (30 mL) at 0 °C was treated with EDC·HCl (627.7 mg, 3.27 mmol, 1.5 equiv)
and HOBt·H2O (552.9 mg, 3.27 mmol, 1.5 equiv). The resulting mixture was stirred at 0 °C for 15
min, then treated with a solution of -hydroxyamino ester 154a2 (351.6 mg, 2.18 mmol) in DMF
(7.5 mL) and stirred at 0 °C to rt for 12 h. The reaction was then quenched with sat aq NaHCO 3
(15 mL) and extracted with EtOAc (3  50 mL). The combined organic layers were washed with
H2O (3  25 mL) and brine (25 mL), dried (Na2SO4), and concentrated in vacuo. Flash
chromatography (100 mL of SiO2, 0–2.5% MeOH in CH2Cl2 gradient elution) afforded 148aa
(632.7 mg, 1.84 mmol, 84%) as a colorless oil that was a 1:1 mixture of diastereomers: 1H NMR
(CDCl3, 500 MHz) δ 6.90 (d, J = 8.7 Hz, 1H), 5.96–5.86 (m, 1H), 5.50–5.43 (m, 1H), 5.34–5.27
(m, 1H), 5.24–5.19 (m, 1H), 4.61–4.55 (m, 2H), 4.51 (t, J = 8.5 Hz, 1H), 4.29–4.19 (m, 2H), 4.17–
4.12 and 4.11–4.06 (2m, 1H), 3.12 and 2.92 (2 br s, 1H), 2.25–2.17 and 2.16–2.07 (2m, 1H), 1.32–
1.28 (m, 3H), 1.30 (s, 3H), 1.26 (s, 3H), 1.00 and 0.97 (2d, J = 6.9 and 6.7 Hz, 3H), 0.95 and 0.92
(2d, J = 6.8 and 6.7 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 171.6, 171.3 and 171.1, 156.3, 132.5,
117.9, 71.9 and 71.8, 65.9, 61.7 and 61.6, 60.3 and 60.2, 59.9 and 59.8, 31.1, 26.8, 26.7, 19.3 and

2

Ma, Z.; Naylor, B. C.; Loertscher, B. M.; Hafen, D. D.; Li, J. M.; Castle, S. L. J. Org. Chem.
2012, 77, 1208.
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19.1, 17.9 and 17.3, 14.1; IR (film) max 3324, 2973, 1729, 1660, 1536, 1214 cm–1; HRMS (ESI)
m/z 345.1976 (MH+, C16H28N2O6H+ requires 345.1981).

Ethyl

2-((S)-2-(((Allyloxy)carbonyl)amino)-3-methylbutanamido)-3-

ethyl-3-hydroxypentanoate (148ab). Subjection of -hydroxyamino ester 154b3 (323.2 mg,
1.71 mmol) to the procedure described above for the synthesis of 148aa with Alloc-Val-OH (155a,
514.8 mg, 2.56 mmol, 1.5 equiv) as coupling partner, stirring for 16 h, and purification by flash
chromatography (75 mL of SiO2, 0–4% MeOH in CH2Cl2 gradient elution) afforded 148ab (498.7
mg, 1.34 mmol, 78%) as a colorless liquid that was a 1:1 mixture of diastereomers: 1H NMR
(CDCl3, 500 MHz) δ 6.69 and 6.63 (2d, J = 8.7 and 8.2 Hz, 1H), 5.97–5.88 (m, 1H), 5.37–5.28
(m, 2H), 5.23 (d, J = 10.4 Hz, 1H), 4.62–4.55 (m, 3H), 4.29–4.17 (m, 2H), 4.14–4.09 and 4.08–
4.03 (2m, 1H), 2.47 (br s, 1H), 2.25–2.17 and 2.16–2.09 (2m, 1H), 1.59–1.44 (m, 4H), 1.31 (t, J =
7.2 Hz, 3H), 1.00 and 0.97 (2d, J = 6.8 and 6.8 Hz, 3H), 0.96–0.91 (m, 6H), 0.87 (t, J = 7.4 Hz,
3H); 13C NMR (CDCl3, 125 MHz) δ 171.8 and 171.7, 171.2, 156.2, 132.6, 117.9 and 117.8, 76.2,
65.9, 61.6 and 61.5, 60.2, 56.8 and 56.7, 31.2, 28.4, 26.7, 19.3 and 19.1, 17.7 and 17.2, 14.1, 7.6,
7.5; IR (film) max 3336, 2969, 1727, 1659, 1530 cm–1; HRMS (ESI) m/z 373.2276 (MH+,
C18H32N2O6H+ requires 373.2294).
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Ethyl

2-((S)-2-(((Allyloxy)carbonyl)amino)-4-oxo-4-(tritylamino)

butanamido)-3-hydroxy-3-methylbutanoate (148ba). Subjection of -hydroxyamino ester
154a (163.6 mg, 1.01 mmol) to the procedure described above for the synthesis of 148aa with
Alloc-Asn(Trt)-OH (155b, 695.2 mg, 1.52 mmol, 1.5 equiv) as coupling partner, stirring for 12 h,
and purification by flash chromatography (75 mL of SiO2, 0–6% MeOH in CH2Cl2 gradient
elution), afforded 148ba (472.7 mg, 0.786 mmol, 77%) as a white film that was a 1:1 mixture of
diastereomers: 1H NMR (CDCl3, 500 MHz) δ 7.38 (d, J = 8.4 Hz, 1H), 7.33–7.23 (m, 9H), 7.18
(d, J = 7.8 Hz, 6H), 6.86 (br s; 1H), 6.43 (d, J = 8.1 Hz, 1H), 5.97–5.85 (m, 1H), 5.31 (dd, J = 17.2,
1.3 Hz, 1H), 5.23 (dd, J = 10.4, 1.2 Hz, 1H), 4.63–4.56 (m, 2H), 4.56–4.51 (m, 1H), 4.47 (d, J =
8.8 Hz, 1H), 4.29–4.16 (m, 2H), 3.11 (dd, J = 15.6, 3.7 Hz, 1H), 2.72–2.63 (m, 1H), 2.69 (br s,
1H), 1.30 (t, J = 7.0 Hz, 3H), 1.21 (s, 3H), 1.14 (s, 3H);

13

C NMR (CDCl3, 125 MHz) δ 171.1,

170.8, 170.2, 156.4, 144.2 (3C), 132.3, 128.7 (6C), 128.0 (6C), 127.1 (3C), 118.0, 71.9, 70.9, 66.1,
61.6, 60.3, 51.7, 37.6, 26.7, 26.4, 14.1; IR (film) max 3330, 2923, 1659, 1524 cm–1; HRMS (ESI)
m/z 602.2831 (MH+, C34H39N3O7H+ requires 602.2822).

Ethyl

2-((S)-2-(((Allyloxy)carbonyl)amino)-4-oxo-4-(tritylamino)

butanamido)-3-ethyl-3-hydroxypentanoate (148bb). Subjection of -hydroxyamino ester 154b
(135.2 mg, 0.714 mmol) to the procedure described above for the synthesis of 148aa with stirring
for 16 h with Alloc-Asn(Trt)-OH (155b, 497.6 mg, 1.09 mmol, 1.5 equiv) as coupling partner and
purification by flash chromatography (60 mL of SiO2, 0–5% MeOH in CH2Cl2 gradient elution),
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afforded 148bb (320.4 mg, 0.509 mmol, 71%) as a white film that was a 1:1 mixture of
diastereomers: 1H NMR (CD3OD, 500 MHz) δ 7.30–7.19 (m, 15H), 6.00–5.91 (m, 1H), 5.34 (d, J
= 17.2 Hz, 1H), 5.21 (d, J = 10.3 Hz, 1H), 4.60–4.56 (m, 2H), 4.55–4.51 (m, 1H), 4.50 (s, 1H),
4.23–4.17 and 4.16–4.09 (2m, 2H), 2.86–2.66 (m, 2H), 1.65–1.45 (m, 4H), 1.27 and 1.26 (2t, J =
7.3 and 7.3 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H), 0.84 and 0.83 (2t, J = 7.5 and 7.4 Hz, 3H); 13C NMR
(CD3OD, 125 MHz) δ 172.1, 170.4 and 170.3, 170.1, 156.7 and 156.6, 144.4 (3C), 132.7, 128.6
(6C), 127.3 (6C), 126.4 (3C), 116.5, 75.6 and 75.5, 70.4, 65.6 and 65.5, 60.9, 57.8 and 57.7, 52.1,
38.2, 27.4, 27.0 and 26.9, 13.0, 6.7, 6.6; IR (film) max 3328, 2970, 1735, 1663, 1522, 1275, 1268
cm–1; HRMS (ESI) m/z 630.3110 (MH+, C36H43N3O7H+ requires 630.3135).

Allyl (2R)-2-((1-Ethoxy-3-hydroxy-3-methyl-1-oxobutan-2-yl)carbamoyl)
pyrrolidine-1-carboxylate (148ca). Subjection of -hydroxyamino ester 154a (220.7 mg, 1.37
mmol) to the procedure described above for the synthesis of 148aa with Alloc-D-Pro-OH (155c,
406.3 mg, 2.04 mmol, 1.5 equiv) as coupling partner and purification by flash chromatography (60
mL of SiO2, 0–6.5% MeOH in CH2Cl2 gradient elution) afforded 148ca (378.8 mg, 1.11 mmol,
81%) as a colorless oil that was a 1:1 mixture of diastereomers: 1H NMR (CD3OD, 500 MHz,
mixture of rotamers and diastereomers) δ 6.03–5.83 (m, 1H), 5.40–5.09 (m, 2H), 4.64–4.52 (m,
2H), 4.46–4.35 (m, 2H), 4.27–4.14 (m, 2H), 3.64–3.56 (m, 1H), 3.55–3.46 (m, 1H), 2.34–2.16 (m,
1H), 2.07–1.85 (m, 3H), 1.33–1.27 (m, 6H); 1.24 (s, 3H); 13C NMR (CD3OD, 125 MHz, mixture
of rotamers and diastereomers) δ 175.2/175.0, 171.7/171.6, 156.7/156.3, 134.2/134.1/134.0,
117.9/117.7/117.6, 72.5/72.4, 67.2, 62.3/62.2, 61.9, 61.6/61.5/61.2, 48.1, 32.6/32.5/31.3/31.2,
27.7/27.4/27.3, 27.2/27.1, 25.4/25.3/24.6/24.5, 14.5; IR (film) max 3417, 2917, 1678, 1540, 1408
cm–1; HRMS (ESI) m/z 343.1824 (MH+, C16H26N2O6H+ requires 343.1824).
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Allyl

(2R)-2-((1-Ethoxy-3-ethyl-3-hydroxy-1-oxopentan-2-yl)carbamoyl)

pyrrolidine-1-carboxylate (148cb). Subjection of -hydroxyamino ester 154b (278.1 mg, 1.47
mmol) to the procedure described above for the synthesis of 148aa with Alloc-D-Pro-OH (155c,
437.9 mg, 2.20 mmol, 1.5 equiv) as coupling partner, stirring for 16 h, and purification by flash
chromatography (75 mL of SiO2, 0–6% MeOH in CH2Cl2 gradient elution) afforded 148cb (431.7
mg, 1.17 mmol, 79%) as a colorless oil that was a 1:1 mixture of diastereomers: 1H NMR (CD3OD,
500 MHz, mixture of rotamers and diastereomers) δ 6.03–5.85 (m, 1H), 5.39–5.11 (m, 2H), 4.64–
4.49 (m, 3H), 4.44–4.33 (m, 1H), 4.28–4.13 (m, 2H), 3.65–3.56 (m, 1H), 3.55–3.47 (m, 1H), 2.36–
2.15 (m, 1H), 2.08–1.84 (m, 3H), 1.72–1.49 (m, 4H), 1.33–1.25 (m, 3H), 0.93 (t, J = 7.6 Hz, 3H),
0.90–0.82 (m, 3H);

13

C NMR (CD3OD, 125 MHz, mixture of rotamers and diastereomers) δ

173.6/173.5, 170.5/170.4, 155.0/154.9, 132.7/132.6, 116.4/116.3/116.2/116.1, 75.6/75.5,
65.9/65.8, 60.8/60.7, 60.3/59.9, 57.7/57.6/57.4, 46.7, 31.1/31.0/29.9/29.8, 27.4, 27.0/26.9,
24.0/23.9/23.0, 13.0, 6.7, 6.6; IR (film) max 3414, 2969, 1679, 1444, 1408 cm–1; HRMS (ESI) m/z
371.2127 (MH+, C18H30N2O6H+ requires 371.2137).

5.2.2 Synthesis of Azlactone Dipeptides 149

Allyl (S)-(2-methyl-1-(5-oxo-4-(propan-2-ylidene)-4,5-dihydrooxazol-2yl)propyl)carbamate (149aa). A solution of dipeptide 148aa (394.2 mg, 1.14 mmol) in 3:1 tBuOH–H2O (20 mL) at 0 °C was treated with LiOH·H2O (239.7 mg, 5.71 mmol, 5.0 equiv) and
stirred at 0 °C for 4 h. The reaction was quenched with 1.0 M HCl solution to adjust the pH to 2,
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and the resulting mixture was extracted with EtOAc (4  30 mL). The combined organic layers
were washed with brine (20 mL), dried (Na2SO4), and concentrated in vacuo. The crude acid (357.9
mg, 1.13 mmol) was then dissolved in anhydrous THF (20 mL), treated with NaOAc (139.4 mg,
1.70 mmol, 1.5 equiv) and Ac2O (540 L, 583 mg, 5.71 mmol, 5.0 equiv), then stirred at rt under
Ar for 12 h. The reaction was quenched with MeOH (10 mL), stirred at rt for 30 min, diluted with
H2O (10 mL), and extracted with EtOAc (4  25 mL). The combined organic layers were washed
with brine (25 mL), dried (Na2SO4), and concentrated in vacuo. Flash chromatography (50 mL of
SiO2, 1% Et3N in 1–10% EtOAc in hexanes gradient elution) afforded 149aa (257.7 mg, 0.919
mmol, 80%) as a colorless oil: [α]25D 18 (c 0.44, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 1H NMR
(CDCl3, 500 MHz) δ 6.01–5.89 (m, 1H), 5.34 (d, J = 17.1 Hz, 1H), 5.31–5.27 (m, 1H), 5.25 (d, J
= 10.9 Hz, 1H), 4.64–4.56 (m, 3H), 2.36 (s, 3H), 2.26 (s, 3H), 2.24–2.17 (m, 1H), 1.02 (d, J = 6.8
Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H); 13C NMR (CDCl3 , 125 MHz) δ 164.9, 162.1, 155.9, 154.7, 132.6,
130.1, 118.0, 66.0, 55.0, 31.3, 22.8, 19.7, 18.9, 17.5; IR (film) max 3293, 2917, 1693, 1650, 1536
cm–1; HRMS (ESI) m/z 281.1484 (MH+, C14H20N2O4H+ requires 281.1457).

Allyl

(S)-(2-methyl-1-(5-oxo-4-(pentan-3-ylidene)-4,5-dihydrooxazol-2-

yl)propyl)carbamate (149ab). Subjection of dipeptide 148ab (338.6 mg, 0.909 mmol) to the
saponification procedure described above for the synthesis of 149aa with 6 h of stirring afforded
307.3 mg (0.892 mmol) of the crude acid. Subjection of this crude mixture to the conditions
described previously with NaOAc (109.9 mg, 1.34 mmol, 1.5 equiv), Ac2O (430 L, 464 mg, 4.55
mmol, 5.1 equiv), and purification by flash chromatography 65 mL of SiO 2, 1% Et3N in 1–10%
EtOAc in hexanes gradient elution) afforded 149ab (208.6 mg, 0.676 mmol, 74%) as a colorless
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oil: [α]25D 14 (c 0.36, CHCl3); 1H NMR (CD3OD, 500 MHz) δ 6.01–5.90 (m, 1H), 5.33 (dd, J =
17.3, 1.6 Hz, 1H), 5.19 (d, J = 10.6 Hz, 1H), 4.56 (d, J = 5.4 Hz, 2H), 4.02 (d, J = 6.8 Hz, 1H),
2.58 (q, J = 7.6 Hz, 2H), 2.28–2.18 (m, 2H), 2.17–2.09 (m, 1H), 1.11 (t, J = 7.4 Hz, 3H), 1.04 (t,
J = 7.5 Hz, 3H), 1.03 (d, J = 7.3 Hz, 3H), 0.99 (d, J = 6.8 Hz, 3H); 13C NMR (CD3OD, 125 MHz)
δ 172.6, 166.5, 157.0, 155.7, 132.9, 121.3, 116.2, 65.2, 60.4, 30.6, 25.4, 24.3, 18.4, 17.0, 12.0,
11.0; IR (film) max 3293, 2966, 1693, 1650, 1561 cm–1; HRMS (ESI) m/z 309.1746 (MH+,
C16H24N2O4H+ requires 309.1770).

Allyl (S)-(3-oxo-1-(5-oxo-4-(propan-2-ylidene)-4,5-dihydrooxazol-2-yl)-3(tritylamino)propyl)carbamate (149ba). A solution of dipeptide 148ba (402.9 mg, 0.670 mmol)
in 3:1 t-BuOH–H2O (16 mL) at 0 °C was treated with LiOH·H2O (141.4 mg, 3.37 mmol, 5.0 equiv)
and stirred at 0 °C for 4 h. The reaction was quenched with sat aq KHSO 4 to adjust the pH to 2,
and the resulting mixture was extracted with EtOAc (4  25 mL). The combined organic layers
were washed with brine (15 mL), dried (Na2SO4), and concentrated in vacuo. The crude acid (363.6
mg, 0.634 mmol) was then dissolved in anhydrous THF (20 mL), treated with NaOAc (78.1 mg,
0.952 mmol, 1.5 equiv) and Ac2O (300 L, 324 mg, 3.17 mmol, 5.0 equiv), then stirred at rt under
Ar for 12 h. The reaction was quenched with MeOH (10 mL), stirred at rt for 30 min, diluted with
H2O (10 mL), and extracted with EtOAc (4  25 mL). The combined organic layers were washed
with brine (15 mL), dried (Na2SO4), and concentrated in vacuo. Flash chromatography (50 mL of
SiO2, 1% Et3N in 2–10% EtOAc in hexanes gradient elution) afforded 149ba (252.4 mg, 0.469
mmol, 70%) as a white solid: [α]25D 2.1 (c 0.86, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 7.31–
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7.23 (m, 9H), 7.17–7.12 (m, 6H), 6.78 (s, 1H), 6.17 (d, J = 8.5 Hz, 1H), 5.97–5.82 (m, 1H), 5.32
(d, J = 17.1 Hz, 1H), 5.21 (d, J = 10.4 Hz, 1H), 5.01–4.91 (m, 1H), 4.64–4.52 (m, 2H), 3.08 (dd, J
= 15.6, 4.3 Hz, 1H), 2.92 (dd, J = 15.5, 4.5 Hz, 1H), 2.35 (s, 3H), 2.19 (s, 3H); 13C NMR (CDCl3,
125 MHz) δ 168.7, 164.8, 161.7, 155.9, 154.5, 144.2 (3C), 132.5, 130.5, 128.6 (6C), 128.0 (6C),
127.2 (3C), 117.7, 70.9, 65.9, 46.9, 37.9, 22.9, 19.7; IR (film) max 3286, 2917, 1794, 1673, 1530,
1447, 1158 cm–1; HRMS (ESI) m/z 538.2273 (MH+, C32H31N3O5H+ requires 538.2297).

Allyl

(S)-(3-oxo-1-(5-oxo-4-(pentan-3-ylidene)-4,5-dihydrooxazol-2-yl)-3-

(tritylamino)propyl)carbamate (149bb). Subjection of dipeptide 148bb (342.7 mg, 0.544 mmol)
to the saponification procedure described above for the synthesis of 149ba afforded 316.4 mg
(0.526 mmol) of the crude acid. Subjection of this crude mixture to the conditions described
previously with NaOAc (65.7 mg, 0.801 mmol, 1.5 equiv), Ac2O (250 L, 270 mg, 2.64 mmol,
5.0 equiv), and purification by flash chromatography (60 mL of SiO 2, 1% Et3N in 1–10% EtOAc
in hexanes gradient elution) afforded 149bb (197.7 mg, 0.349 mmol, 64%) as a white solid: [α]25D
5.4 (c 1.0, CHCl3); 1H NMR (CDCl3, 500 MHz) δ 7.31–7.22 (m, 9H), 7.14–7.11 (m, 6H), 6.78
(s, 1H), 6.15 (d, J = 8.6 Hz, 1H), 5.98–5.84 (m, 1H), 5.32 (d, J = 17.3 Hz, 1H), 5.21 (d, J = 10.5
Hz, 1H), 5.00–4.92 (m, 1H), 4.64–4.52 (m, 2H), 3.10 (dd, J = 15.6, 4.4 Hz, 1H), 2.92 (dd, J = 15.5,
4.7 Hz, 1H), 2.85–2.71 (m, 2H), 2.69–2.54 (m, 2H), 1.14 (t, J = 7.5 Hz, 3H), 1.09 (t, J= 7.7 Hz,
3H); 13C NMR (CDCl3, 125 MHz) δ 168.7, 165.4, 164.7, 161.9, 155.9, 144.2 (3C), 132.5, 129.6,
128.6 (6C), 128.0 (6C), 127.2 (3C), 117.6, 71.0, 65.9, 47.0, 37.9, 26.6, 23.4, 12.5, 12.3; IR (film)
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max 3277, 2918, 1789, 1648, 1526, 1447, 1268 cm–1; HRMS (ESI) m/z 566.2639 (MH+,
C34H35N3O5H+ requires 566.2610).

Allyl (R)-2-(5-oxo-4-(propan-2-ylidene)-4,5-dihydrooxazol-2-yl)pyrrolidine1-carboxylate (149ca). Subjection of dipeptide 148ca (268.6 mg, 0.784 mmol) to the
saponification procedure described above for the synthesis of 149aa afforded 236.1 mg (0.751
mmol) of the crude acid. Subjection of this crude mixture to the conditions described previously
with NaOAc (92.8 mg, 1.13 mmol, 1.5 equiv), Ac2O (360 L, 389 mg, 3.81 mmol, 5.1 equiv), and
purification by flash chromatography (50 mL of SiO2, 1% Et3N in 2–10% EtOAc in hexanes
gradient elution) afforded 149caa (157.9 mg, 0.567 mmol, 72%) as a colorless oil: [α]25D +93 (c
0.64, CHCl3); 1H NMR (CDCl3, 500 MHz, ca. 1.2:1 mixture of rotamers) δ 5.99–5.90 and 5.88–
5.78 (2m, 1H), 5.33 and 5.25 (2d, J = 17.2 and 18.8 Hz, 1H), 5.22 and 5.13 (2d, J = 10.9 and 10.5
Hz, 1H), 4.75–4.68 (m, 1H), 4.65–4.59 and 4.52 (m and dd, J = 13.7, 5.1 Hz, 1H), 4.61 (d, J = 5.4
Hz, 1H), 3.68–3.59 (m, 1H), 3.59–3.50 (m, 1H), 2.35 and 2.33 (2s, 3H), 2.32–2.26 (m, 1H), 2.24
(s, 3H), 2.18–2.03 (m, 2H), 2.02–1.92 (m, 1H); 13C NMR (CDCl3, 125 MHz, ca. 1.2:1 mixture of
rotamers) δ 165.3, 165.1, 163.1 and 162.9, 154.5 and 154.1, 132.8 and 132.6, 130.7 and 130.5,
117.4 and 117.0, 66.0 and 65.9, 55.7 and 55.1, 46.9 and 46.5, 31.2 and 30.4, 24.3 and 23.4, 22.8
and 22.7, 19.7; IR (film) max 2917, 1794, 1707, 1675, 1406, 1158 cm–1; HRMS (ESI) m/z
279.1325 (MH+, C14H18N2O4H+ requires 279.1300).
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Allyl (R)-2-(5-oxo-4-(pentan-3-ylidene)-4,5-dihydrooxazol-2-yl)pyrrolidine-1carboxylate (6bb). Subjection of dipeptide 148cb (337.4 mg, 0.911 mmol) to the saponification
procedure described above for the synthesis of 149aa afforded 308.2 mg (0.900 mmol) of the crude
acid. Subjection of this crude mixture to the conditions described previously with NaOAc (110.9
mg, 1.35 mmol, 1.5 equiv), Ac2O (430 L, 464 mg, 4.55 mmol, 5.1 equiv), and purification by
flash chromatography (75 mL of SiO2, 1% Et3N in 1–10% EtOAc in hexanes gradient elution)
afforded 149cb (204.8 mg, 0.668 mmol, 73%) as a colorless oil: [α]25D +83 (c 1.0, CHCl3); 1H
NMR (CDCl3, 500 MHz, ca. 1.1:1 mixture of rotamers) δ 6.00–5.89 and 5.87–5.76 (2m, 1H), 5.32
and 5.23 (2d, J = 17.8 and 18.5 Hz, 1H), 5.22 and 5.12 (2d, J = 9.4 and 10.4 Hz, 1H), 4.74 and
4.69 (2dd, J = 8.2, 3.0 Hz and 8.1, 3.4 Hz, 1H), 4.65–4.58 and 4.50 (m and dd, J = 13.6, 5.2 Hz,
1H), 4.61 (d, J = 4.6 Hz, 1H), 3.68–3.60 (m, 1H), 3.59–3.51 (m, 1H), 2.83–2.74 (m, 2H), 2.69–
2.59 (m, 2H), 2.34–2.24 (m, 1H), 2.18–2.03 (m, 2H), 2.01–1.91 (m, 1H), 1.17–1.07 (m, 6H); 13C
NMR (CDCl3, 125 MHz, ca. 1.1:1 mixture of rotamers) δ 165.2, 165.0 and 164.9, 163.2 and 163.1,
154.5 and 154.2, 132.8 and 132.6, 129.8 and 129.6, 117.4 and 117.1, 66.0 and 65.9, 55.7 and 55.1,
46.9 and 46.5, 31.2 and 30.4, 26.6, 24.3 and 23.6, 23.4, 12.5 and 12.4, 12.3; IR (film) max 2975,
1791, 1709, 1668, 1406, 1156 cm–1; HRMS (ESI) m/z 307.1625 (MH+, C16H22N2O4H+ requires
307.1613).

5.2.3 General Procedures for Solid-Phase Peptide Synthesis
Attachment of C-terminal amino acid to resin. Rink amide MBHA resin (100–200 mesh,
100 μmol) was added to a fritted polypropylene syringe. The resin was swelled in CH2Cl2 (10 min),
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and then in DMF (5 min). The swelling solvents were drained from the resin using a vacuum
manifold. After Fmoc deprotection (see below for procedure, repeated twice), the amino acid was
coupled to the resin (see below for procedure, repeated twice).
Fmoc Deprotection. The resin (100 mol) was treated with piperidine (20% solution in
DMF, 5.0 mL) and allowed to stand for 5 min. The solution was drained from the resin using a
vacuum manifold, and additional piperidine (20% solution in DMF, 5.0 mL) was added. The
resulting mixture was stirred twice at 80 °C in a microwave oven for 4 min. The solution was
drained from the resin using a vacuum manifold, and the resin was rinsed with DMF (5  10 mL).
Peptide coupling. The Fmoc-protected amino acid (500 μmol, 5 equiv) and HBTU (190
mg, 500 μmol, 5 equiv) were dissolved by vortexing in a 0.1 M HOBt solution in NMP (5.0 mL,
500 μmol, 5 equiv). iPr2NEt (176 μL, 1000 μmol, 10 equiv) was added to this solution, and it was
allowed to stand for ca. 1 min. The solution was added to the resin (100 mol), and the resulting
mixture was stirred at 70 °C in a microwave oven for 10 min. The solution was drained from the
resin using a vacuum manifold, and the resin was rinsed with DMF (5  10 mL). The N-terminal
amino acid of each peptide (i.e., Arg) was coupled by gently stirring the solution at rt under Ar for
ca. 10–12 h after the microwave heating was completed.
Coupling of azlactones 149 with resin-bound peptides. A solution of 149 (500 μmol, 5
equiv) and Et3N (150 L, 1.08 mmol, 10 equiv) in NMP (10 mL) was added to the resin-bound
peptide (100 mol). The resulting mixture was gently stirred at 80 °C for 24–36 h. The solution
was drained from the resin using a fritted polypropylene syringe into a 20 mL glass vial (note: the
unreacted azlactone present in the solution can be reused), and the resin was rinsed with DMF (5
 10 mL). Any unreacted amines were then capped by addition of a solution of Ac 2O (1.0 mL,
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1.08 g, 10.6 mmol, 106 equiv) and Et 3N (200 L, 145.2 mg, 1.44 mmol, 14.4 equiv.) in CH2Cl2 (5
mL), followed by stirring at rt under Ar for 90 min and washing with CH 2Cl2 (5  10 mL).
Alloc deprotection. The resin-bound peptide (100 mol) was placed under an Ar
atmosphere and treated with a solution of PhSiH3 (700 L, 613.9 mg, 5.67 mmol, 56.7 equiv) in
CH2Cl2 (3 mL) with stirring, followed by addition of a solution of Pd(PPh3)4 (56.8 mg, 49.2 mol,
0.49 equiv) in CH2Cl2 (3 mL). The resulting mixture was stirred at rt under Ar for 20 min. The
resin was rinsed with CH2Cl2 (5 × 10 mL), and the deprotection protocol was repeated once.
Acetylation of the N-terminus of resin-bound peptides. The N-terminus of each peptide
was capped by addition of a solution of Ac2O (1.0 mL, 1.08 g, 10.6 mmol, 106 equiv) and Et 3N
(200 L, 145.2 mg, 1.44 mmol, 14.4 equiv.) in CH2Cl2 (5 mL), followed by stirring at rt under Ar
for 2 h. The resin was then rinsed with CH2Cl2 (5  10 mL).
Cleavage of peptide from resin and purification. The resin-bound peptide (100 mol)
was treated carefully with a solution of phenol (500 mg, 5.31 mmol), H2O (500 μL), thioanisole
(500 μL, 528.5 mg, 4.26 mmol), ethanedithiol (250 μL, 280.8 mg, 2.98 mmol), and
triisopropylsilane (100 μL, 77.3 mg, 488 mol) in TFA (8.0 mL) in order to avoid the buildup of
excess CO2 pressure in the reaction vessel. The resulting mixture was stirred at rt for ca. 4 h, and
the peptide was precipitated by filtering the mixture and pouring the filtrate into cold Et 2O (40
mL). The resin was rinsed with TFA (3 mL), and the precipitate was collected by centrifugation.
The crude peptide was lyophilized and purified by HPLC (see entries for individual peptides for
elution conditions).
Synthesis of cyclic and random coil control peptides (167–168). Ac-Cys-Trp-Val-GluVal-Asn-Gly-Orn-Lys-Ile-Leu-Gln-Cys-NH2 (167a) and Ac-Cys-Trp-Val-Glu-Val-ΔVal-Gly113

Orn-Lys-Ile-Leu-Gln-Cys-NH2 (167b) were synthesized according to the previously described
general procedures and purified by HPLC. They were then cyclized by stirring in open air for ca.
24 h in a 10 mM phosphate buffer solution (pH 7.5) containing 5% DMSO, affording cyclic
controls 167a and 167b respectively. Random coil peptides 168a, 168b, 168c, and 168d were
synthesized according to the previously described general procedures. Azlactones 149aa and AcΔVal4 were used to synthesize 168c and 168d respectively.
Peptide Concentration Determination and NMR Sample Preparation. Peptide
solutions were prepared in 20 mM sodium phosphate buffer (pH 7), and peptide concentrations
were determined spectroscopically based on tryptophan absorbance at 280 nm in 6 M guanidine
hydrochloride (Trp 280 = 5690 M–1cm–1). NMR samples were prepared with 1–3.5 mM peptide in
10% v/v D2O/H2O buffered to pD 3.9 with 5000 M NaOAc-d3.

4

El-Baba, S., Nuzillard, J.M., Poulin, J.C., Kagan, H.B. Tetrahedron 1986, 42, 3851.
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5.2.4 Tabulated 1H NMR Data for Peptides
Table 5.1. Ac-R-W-V-E-V-N-G-O-K-I-L-Q-NH2 (153a).
Amide α

β

Others (γ, δ, ε)

Arg

8.11

4.38

1.65, 1.71

γ CH2 1.52; δ CH2 3.15; ε H 7.14

Trp

8.34

5.09

3.09

H1 10.2; H2 7.25; H4 7.50; H6 7.08; H7 7.34

Val

9.00

4.45

2.04

γ CH3 0.871, 0.889

Glu

8.55

4.92

1.93, 2.02

γ CH2 2.28

Val

8.90

4.22

1.96

γ CH3 0.928

Asn

9.41

4.48

2.77, 3.07

δ NH2 6.96, 7.64

Gly

8.64

3.75, 4.09

Orn

7.87

4.62

1.83, 1.87

γ CH2 1.73; δ CH2 3.05; ε NH 7.66

Lys

8.51

4.74

1.70

γ CH2 1.23; δ CH2 1.36; ε CH2 2.58; ζ NH3 7.28

Ile

9.11

4.57

1.89

γ CH2 1.21, 1.43; δ CH3 0.836; γ CH3 0.902

Leu

8.35

4.10

1.09, 1.37

γ CH 0.792; δ CH3 0.319, 0.529

Gln

8.67

4.33

1.89, 2.05

γ CH2 2.28; ε NH2 6.89, 7.36
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Table 5.2. Ac-R-W-V-E-V-p-G-O-K-I-L-Q-NH2 (153b).
H

α

β

Others (γ, δ, ε)

Arg

8.07

4.41

1.64, 1.72

γ CH2 1.53; δ CH2 3.16; ε NH 6.88

Trp

8.36

5.13

3.08

H1 10.20; H2 7.23; H4 7.27; H5 7.05; H7 7.49

Val

9.25

4.51

2.05

γ CH3 0.889, 0.873

Glu

8.59

5.06

2.03, 1.95

γ CH2 2.33

Val

8.98

4.63

1.99

γ CH3 0.941

4.38

2.20, 2.40

γ CH2 2.01, 2.08; δ CH2 3.88

D-Pro
Gly

8.62

3.80, 4.04

Orn

7.93

4.66

1.85

γ CH2 1.71; δ CH2 3.03, ε NH3 7.65

Lys

8.48

4.86

1.67

γ CH2 1.20; δ CH2 1.28; ε CH2 2.48

Ile

9.24

4.62

1.88

γ CH2 1.19, 1.40; δ CH3 0.816; γ CH3 0.889

Leu

8.36

4.02

0.966,
1.32

γ CH 0.595; δ CH3 0.166, 0.445

Gln

8.73

4.33

1.86, 2.03

γ CH2 2.25; ε NH2 7.71, 7.12

Table 5.3. Ac-R-W-V-E-V-∆Val-G-O-K-I-L-Q-NH2 (152aa).
H

α

β

Others (γ, δ, ε)

Arg

8.08

4.41

1.73, 1.65

γ CH2 1.54; δ CH2 3.16; ε NH 7.14

Trp

8.34

5.15

3.04, 3.09

H1 10.2; H2 7.24; H4 7.29; H6 7.06; H7 7.50

Val

9.24

4.54

2.08

γ CH3 0.880

Glu

8.57

5.14

2.01, 1.93

γ CH2 2.27, 2.30

Val

9.08

4.38

1.96

γ CH3 0.994, 0.955

∆Val

10.3

Gly

8.63

4.11, 3.73

Orn

7.98

4.66

1.72

γ CH2 1.85; δ CH2 3.03; ε NH3 7.65

Lys

8.50

4.82

1.67, 1.35

γ CH2 1.20; δ CH2 1.28, 1.35; ε CH2 2.50, 2.45; ζ NH37.20

Ile

9.26

4.63

1.90

γ CH2 1.21, 1.41; δ CH3 0.813; γ CH3 0.888

Leu

8.35

4.04

0.990, 1.33

γ CH 0.641; δ CH3 0.194, 0.454

Gln

8.72

4.33

1.87, 2.03

γ CH2 2.26; ε NH2 7.12, 7.71

γ CH3 1.99, 1.89
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Table 5.4. Ac-R-W-V-E-V-∆Env-G-O-K-I-L-Q-NH2 (152ab).
H

α

β

Others (γ, δ, ε)

Arg

8.08

4.42

1.66, 1.73

γ CH2 1.54; δ CH2 3.17; ε NH 7.15

Trp

8.35

5.14

3.04, 3.10

H1 10.2; H2 7.24; H4 7.31; H5 7.07; H7 7.51

Val

9.18

4.52

2.07

γ CH3 0.885, 0.907

Glu

8.57

5.09

2.22

γ CH2 1.92, 2.00

Val

9.04

4.41

1.99

γ CH3 0.965, 0.982

∆Env

10.1

Gly

8.65

3.76, 4.11

Orn

7.97

4.67

1.87

γ CH2 1.74; δ CH2 3.05; ε NH3 7.63

Lys

8.53

4.83

1.68

γ CH2 1.21; δ CH2 1.30, 1.38; ε CH2 2.52

Ile

9.23

4.62

1.89

γ CH2 1.21, 1.42; δ CH3 0.829; γ CH3 0.898

Leu

8.34

4.05

1.01, 1.34

γ CH 0.663; δ CH3 0.224, 0.476

Gln

8.71

4.34

1.88, 2.05

γ CH2 2.27; ε NH2 7.71, 7.12

γ CH2 2.36, 2.20; δ CH3 1.05, 0.992

Table 5.5. Ac-R-W-V-E-V-N-∆Val-O-K-I-L-Q-NH2 (152ba).
H

α

β

Others (γ, δ, ε)

Arg

8.12

4.30

1.64

γ CH2 1.47; δ CH2 3.11; ε NH 7.11

Trp

8.27

4.97

3.14

H1 10.18; H2 7.23; H4 7.42; H5 7.08; H7 7.49

Val

8.62

4.30

2.01

γ CH3 0.851

Glu

8.45

4.75

1.90, 1.98

γ CH2 2.23

Val

8.70

4.18

1.99

γ CH3 0.915

Asn

9.15

4.61

2.80, 3.01

δ NH2 6.95, 7.62

∆Val

9.34

Orn

7.78

4.49

1.72, 1.76

γ CH2 1.86; δ CH2 3.04; ε NH3 7.64

Lys

8.36

4.57

1.73

γ CH2 1.26; δ CH2 1.42; ε CH2 2.68

Ile

8.76

4.39

1.87

γ CH2 1.17, 1.42; δ CH3 0.805; γ CH3 0.805

Leu

8.33

4.16

1.42, 1.25

γ CH 1.05; δ CH3 0.484, 0.619

Gln

8.49

4.30

1.91, 2.05

γ CH2 2.30; ε NH2 7.12, 7.62

γ CH3 1.81, 0.917
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Table 5.6. Ac-R-W-V-E-V-N-∆Env-O-K-I-L-Q-NH2 (152bb).
H

α

β

Others (γ, δ, ε)

Arg

8.14

4.27

1.64

γ CH2 1.47; δ CH2 3.11; ε NH 7.11

Trp

8.25

4.92

3.18

1H 10.2; H2 7.24; H5 7.10; H7 7.48

Val

8.44

4.25

2.01

γ CH3 0.856

Glu

8.40

4.66

1.97, 2.09

γ CH2 2.32

Val

8.58

4.16

2.02

γ CH3 0.935

Asn

8.98

4.70

2.80, 3.01

δ NH2 7.00, 7.64

∆Env

9.21

Orn

7.85

4.41

1.87

γ CH2 1.74; δ CH2 3.04; ε NH3 7.65

Lys

8.24

4.50

1.77

γ CH2 1.30; δ CH2 1.49 ε CH2 2.75; ζ NH3 7.41

Ile

8.61

4.30

1.90

γ CH2 1.18, 1.45; δ CH3 0.804; γ CH3 0.879

Leu

8.33

4.19

1.39, 1.48

γ CH 1.23; δ CH3 0.585, 0.685

Gln

8.62

4.30

2.09

γ CH2 2.43; ε NH2 7.15, 7.57

γ CH2 2.139, 2.215; δ CH3 0.971

Table 5.7. Ac-R-W-V-E-V-p-∆Val-O-K-I-L-Q-NH2 (152ca).
H

α

β

Others (γ, δ, ε)

Arg

8.08

4.40

1.71, 1.63

γ CH2 1.513, δ CH2 3.15, ε CH 7.13

Trp

8.35

5.11

3.06

H1 10.2; H2 7.23; H4 7.50; H6 7.05; H7 7.30

Val

9.15

4.48

2.05

γ CH2 0.876

Glu

8.55

5.07

1.89, 1.97

γ CH2 2.16, 2.22

Val

8.95

4.62

2.00

γ CH3 0.947

4.42

2.19, 2.47

γ CH2 2.10; δ CH2 3.88, 3.94

D-Pro
∆Val

9.25

γ CH3 1.80, 2.18

Orn

7.77

4.63

1.80, 1.86

γ CH2 1.73; δ CH2 3.03; ε NH3 7.64

Lys

8.48

4.82

1.67

γ CH2 1.20; δ CH2 1.30; ε CH2 2.53

Ile

9.17

4.58

1.87

γ CH2 1.19, 1.40; δ CH3 0.814; γ CH3 0.885

Leu

8.36

4.04

1.01, 1.34

γ CH 0.671; δ CH3 0.217, 0.470

Gln

8.69

4.32

1.86, 2.03

γ CH2 2.26; ε NH2 6.89, 7.33
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Table 5.8. Ac-R-W-V-E-V-p-∆Env-O-K-I-L-Q-NH2 (152cb).
H

α

β

Others (γ, δ, ε)

Arg

8.08

4.39

1.64, 1.71

γ CH2 1.52; δ CH2 3.15; ε NH 7.14

Trp

8.32

5.10

3.07

H1 10.2; H2 7.23; H4 7.31; H5 7.05; H7 7.50

Val

9.10

4.48

2.07

γ CH3 0.884

Glu

8.53

5.09

1.90, 1.97

γ CH2 2.14, 2.29

Val

8.89

4.61

2.01

γ CH3 0.955

4.44

2.17, 2.47

γ CH2 2.09; δ CH2 3.87, 3.97

D-Pro
∆Env

9.33

γ CH2 2.23, 2.061; δ CH3 0.969

Orn

7.78

4.62

1.88

γ CH2 1.74; δ CH2 3.05; ε NH3 7.63

Lys

8.44

4.82

1.67

γ CH2 1.21; δ CH2 1.34; ε CH2 2.55

Ile

9.12

4.56

1.88

γ CH2 1.20, 1.42; δ CH3 0.823; γ CH3 0.891

Leu

8.36

4.06

1.36, 1.06

γ CH2 0.730; δ CH3 0.258, 0.499

Gln

8.66

4.33

1.89, 2.05

γ CH2 2.27; ε NH2 7.12, 7.69

Table 5.9. c[Ac-C-R-W-V-E-V-∆Val-G-O-K-I-L-Q-C-NH2] (167b).
H

α

β

Others (γ, δ, ε)

Cys

8.38

5.23

3.00, 2.41

Arg

8.73

4.62

1.67, 1.81

γ CH2 1.51; δ CH2 3.18; ε NH 7.12

Trp

8.66

5.15

3.10, 2.96

H1 10.2; H2 7.25; H4 7.29; H5 7.01; H7 7.50

Val

9.55

4.61

2.09

γ CH3 0.888

Glu

8.54

5.16

1.99, 1.90

γ CH2 2.18, 2.19

Val

9.12

4.40

1.95

γ CH3 0.968

∆Val

10.3

Gly

8.66

3.72, 4.13

Orn

7.98

4.70

1.86

γ CH2 1.72; δ CH2 3.04; ε NH3 7.64

Lys

8.53

4.99

1.75

γ CH2 1.38; δ CH2 1.38; ε CH2 2.56

Ile

9.40

4.71

1.86

γ CH2 1.17, 1.41; γ CH3 0.826; δ CH3 0.888

Leu

8.35

3.91

0.772, 1.31

γ CH2 0.379; δ CH3 -0.338, 0.078

Gln

9.05

4.58

1.83, 2.08

γ CH2 2.24

Cys

8.94

5.05

2.94, 3.04

δ CH2 0.985, 1.89
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168b

167a
Amino Acid

Hα

Cys

5.22

Arg

4.62

Trp

5.14

Val

4.59

Glu

5.04

Val

4.25

Asn

4.41

Gly

3.69, 4.14

Orn

4.70

Lys

4.97

Ile

4.72

Leu

3.90

Gln
Cys

Amino Acid

Hα

Asn

4.70

Gly

3.96

Orn

4.36

Lys

4.32

Ile

4.15

Leu

4.40

Gln

4.32
168c

Amino Acid

Hα

Arg

4.18

Trp

4.73

Val

4.01

4.57

Glu

4.27

5.05

Val

4.15

∆Val

-

Gly

3.94
168d

168a

Amino Acid

Hα

∆Val

-

Gly

3.94

4.00

Orn

4.35

Glu

4.25

Lys

4.30

Val

4.09

Ile

4.13

Asn

4.69

Leu

4.38

Gly

3.91

Gln

4.31

Amino Acid

Hα

Arg

4.18

Trp

4.72

Val
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5.2.5 Procedures for proteolysis assays
Proteolysis assays for 153a and its analogues
Pronase E from Streptomyces griseus (EC 3.4.24.31) was purchased from EMD Millipore.
This mixture of enzymes was dissolved in 1X PBS buffer (10 mM sodium phosphate, 137 mM
NaCl, 2.7 mM KCl buffer, pH 7.4) at a concentration of 0.128 mg/mL. Then, solutions of each
peptide (153a, 152aa, 152ab, 152ba, and 152bb) in 1X PBS buffer (0.10 mM, 1.5 mL) at 37 °C
were treated with an aliquot (5 µL) of the pronase E solution. Aliquots (50 L) were removed after
0, 30, 60, 90, 150, 210, 270, 360 180, 300, and 360 min. The aliquots were quenched with 25%
v/v glacial acetic acid (10 L), diluted to 75 µL with 1X PBS buffer, and analyzed by HPLC
(Phenomenex Jupiter C18, 5 m particle size, 300 Å pore size, 4.6  250 mm, 40 L injection
volume, 10%–60% CH3CN in H2O gradient over 50 min, then 95% CH3CN in H2O for 10 min,
flow rate: 1 mL/min).
Proteolysis assays for 153b and its analogues
Pronase E from Streptomyces griseus (EC 3.4.24.31) was purchased from EMD Millipore.
This mixture of enzymes was dissolved in 1X PBS buffer (10 mM sodium phosphate, 137 mM
NaCl, 2.7 mM KCl buffer, pH 7.4) at a concentration of 0.462 mg/mL. Then, solutions of each
peptide (153b, 152ca, and 152cb) in 1X PBS buffer (0.40 mM, 1.5 mL) at 37 °C were treated with
an aliquot (10 µL) of the pronase E solution. Aliquots (50 L) were removed after 0, 30, 60, 90,
150, 210, 270, 360 180, 300, and 360 min. The aliquots were quenched with glacial acetic acid (10
L), diluted to 75 µL with 1X PBS buffer, and analyzed by HPLC (Phenomenex Jupiter C18, 5
m particle size, 300 Å pore size, 4.6  250 mm, 40 L injection volume, 10%–60% CH3CN in
H2O gradient over 50 min, then 95% CH3CN in H2O for 10 min, flow rate: 1 mL/min).
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5.2.6 Procedure for circular dichroism (CD) experiments
Peptide solutions were prepared in 20 mM sodium phosphate buffer (pH 7.4), and
concentrations were determined spectroscopically based on tryptophan absorbance at 280 nm in
6 M guanidine hydrochloride (Trp 280 = 5690 M–1cm–1). 0.10 mM solutions of 153a and 152aaa
in 10 mM sodium phosphate buffer (pH 7.4) and 6 M guanidine hydrochloride were used to
perform wavelength scans in duplicate at 25 °C. 0.10 mM solutions of 153b and 152ca in 10 mM
sodium phosphate buffer (pH 7.4) and 2.5 M urea were used to run wavelength scans in duplicate
at 25 °C.

5.3

Procedure for the synthesis of NTA (172)

(S)-2,4-Dimethylpentanoic acid (216). A solution of amide 2155 (4.24 g, 15.3 mmol)
in 9N H2SO4–dioxane (1:1, 100 mL) was stirred at 105 °C for 12 h. The resulting mixture was
cooled to 0 °C, stirred for 15 min, and then quenched by addition of 50% w/w aq NaOH until pH
≥10. The mixture was extracted with CH2Cl2 (3 × 75 mL) to remove the pseudoephedrine auxiliary.
The aqueous layer was then acidified with 6N H2SO4 to pH ≤2 and extracted with CH2Cl2 (3 × 100
mL). The combined organic layers were washed with 1N HCl (2  25 mL), dried (Na2SO4), and
concentrated in vacuo to afford 216 (1.558 g, 12.0 mmol, 78%) as a yellow oil: [α]25D +19 (c 5.2,
Et2O), lit. 6 [α]25D +18.8 (c 5.2, Et2O), 1H NMR (CDCl3, 500 MHz) δ COOH (1H), 2.58–2.52 (m,
1H), 1.67–1.60 (m, 1H), 1.28–1.23 (m, 2H), 1.18 (d, J = 7.0 Hz, 3H), 0.93 (d, J = 6.0 Hz, 3H), 0.90
(d, J = 6.0 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 182.8, 42.7, 37.3, 25.8, 22.5, 22.4, 17.3; IR

5
6

J. A. Turk, G. S. Visbal, M. A. Lipton, J. Org. Chem. 2003, 68, 7841.
Levene P. A.; Bass, L. W. J. Biol. Chem. 1926, 70, 211.
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(film) max 2959, 1709, 1469 cm–1 HRMS (ESI) m/z 131.1076 (MH+, C7H14O2H+ requires
131.1072).

(4S)-2,2,4,6-tetramethylheptane-1,3-diol (218). A solution of acid 216 (1.51 g,
11.6 mmol) in anhydrous CH2Cl2 (50 mL) at rt under Ar was treated with InBr3 (411.3 mg, 1.16
mmol, 0.1 equiv) and (MeO)3SiH (1.63 mL, 1.56 g, 12.8 mmol, 1.1 equiv), then stirred for 5 min.
Evolution of H2 was observed. Silyl ketene acetal 217 (5.00 mL, 4.29 g, 24.6 mmol, 2.1 equiv)
was added to the resulting suspension, which turned light yellow. The mixture was stirred at 50 °C
under Ar for 3.5 h, then at 0 °C for 30 min. It was then diluted with anhydrous THF (10 mL) and
treated slowly with LiAlH4 (1.53 g, 40.3 mmol, 3.5 equiv), at which point the yellow suspension
turned bright orange. The resulting mixture was stirred at rt under Ar for 12 h, then cooled to 0 °C
and quenched by the slow addition of H2O (2.0 mL), 10% aq NaOH (2.5 mL), and H2O (6.0 mL).
The resulting mixture was stirred at rt for 30 min, then filtered through a sintered glass filter. The
precipitate was washed with CH2Cl2 (5 × 50 mL). The combined organic layers were washed with
sat aq NH4Cl (25 mL), dried (Na2SO4), and concentrated in vacuo. Flash chromatography (65 mL
of SiO2, 5–35% EtOAc in hexanes gradient elution), afforded 218 (1.40 g, 7.43 mmol, 64%) as a
light yellow oil that was a mixture of diastereomers. 1H NMR (CDCl3, 500 MHz) δ;

13

C NMR

(CDCl3, 125 MHz) δ; IR (film) ν max cm–1 ; HRMS (ESI) m/z 189.1827 (MH+, C11H24O2H+ requires
189.1810).

5.4

Spectra and chromatograms
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ROESY Spectra. The spectra are presented with ROESY peaks in orange and TOCSY peaks
superimposed in black for comparison. Peak labels use the standard CCPNMR nomenclature and
their corresponding cross-peaks are marked with a crosshair.
ROESY Spectrum of 153a.

ROESY Spectrum of 153b.
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ROESY Spectrum of 152aa.

ROESY Spectrum of 152ab.
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ROESY Spectrum of 152ba.

ROESY Spectrum of 152bb.
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ROESY Spectrum of 152ca.

ROESY Spectrum of 152cb.
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Figure 5.1. Analytical HPLC data for peptide 153a after preparative purification. Sample was
injected onto a C18 analytical column (4.6 mm × 25 cm) and eluted using a linear gradient of
10–60% CH3CN in H2O (constant 0.1% TFA) over 50 min.

Figure 5.2. Analytical HPLC data for peptide 153b after preparative purification. Sample was
injected onto a C18 analytical column (4.6 mm × 25 cm) and eluted using a linear gradient of 10–
60% CH3CN in H2O (constant 0.1% TFA) over 50 min.
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Figure 5.3. Analytical HPLC data for peptide 152aa after preparative purification. Sample was
injected onto a C18 analytical column (4.6 mm × 25 cm) and eluted using a linear gradient of 10–
60% CH3CN in H2O (constant 0.1% TFA) over 50 min.

Figure 5.4. Analytical HPLC data for peptide 152ab after preparative purification. Sample was
injected onto a C18 analytical column (4.6 mm × 25 cm) and eluted using a linear gradient of 10–
60% CH3CN in H2O (constant 0.1% TFA) over 50 min (run was terminated ~25 min after the
product eluted).
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Figure 5.5. Analytical HPLC data for peptide 152ba after preparative purification. Sample was
injected onto a C18 analytical column (4.6 mm × 25 cm) and eluted using a linear gradient of 20–
60% CH3CN in H2O (constant 0.1% TFA) over 40 min.

Figure 5.6. Analytical HPLC data for peptide 152bb after preparative purification. Sample was
injected onto a C18 analytical column (4.6 mm × 25 cm) and eluted using a linear gradient of
10–60% CH3CN in H2O (constant 0.1% TFA) over 38 min (run was terminated ~15 min after the
product eluted).
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Figure 5.7. Analytical HPLC data for peptide 152ca after preparative purification. Sample was
injected onto a C18 analytical column (4.6 mm × 25 cm) and eluted using a linear gradient of 10–
60% CH3CN in H2O (constant 0.1% TFA) over 50 min.

Figure 5.8. Analytical HPLC data for peptide 152cb after preparative purification. Sample was
injected onto a C18 analytical column (4.6 mm × 25 cm) and eluted using a linear gradient of 10–
60% CH3CN in H2O (constant 0.1% TFA) over 50 min.
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Figure 5.9. Analytical HPLC data for peptide 167a after preparative purification. Sample was
injected onto a C18 analytical column (4.6 mm × 25 cm) and eluted using a linear gradient of 10–
40% CH3CN in H2O (constant 0.1% TFA) over 25 min.

Figure 5.10. Analytical HPLC data for peptide 167b after preparative purification. Sample was
injected onto a C18 analytical column (4.6 mm × 25 cm) and eluted using a linear gradient of 10–
60% CH3CN in H2O (constant 0.1% TFA) over 50 min.
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Figure 5.11. Analytical HPLC data for peptide 168a after preparative purification. Sample was
injected onto a C18 analytical column (4.6 mm × 25 cm) and eluted using a linear gradient of 10–
60% CH3CN in H2O (constant 0.1% TFA) over 50 min.

Figure 5.12. Analytical HPLC data for peptide 168b after preparative purification. Sample was
injected onto a C18 analytical column (4.6 mm × 25 cm) and eluted using a linear gradient of 10–
28% CH3CN in H2O (constant 0.1% TFA) over 35 min.
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Figure 5.13. Analytical HPLC data for peptide 168c after preparative purification. Sample was
injected onto a C18 analytical column (4.6 mm × 25 cm) and eluted using a linear gradient of 10–
60% CH3CN in H2O (constant 0.1% TFA) over 50 min.

Figure 5.14. Analytical HPLC data for peptide 168d after preparative purification. Sample was
injected onto a C18 analytical column (4.6 mm × 25 cm) and eluted using a linear gradient of 10–
28% CH3CN in H2O (constant 0.1% TFA) over 35 min (run was terminated ~25 min after the
product eluted).
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